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Abstract 
COPD is linked to inflammatory mediators that orchestrate the disease progression, 
mainly in the small airways and in parenchymal tissue. Inflammatory mediators, such as 
cytokines, chemokines and oxygen free radicals, orchestrate the inflammatory response, 
causing disruption of the epithelial surface and the surrounding microenvironment in the 
lung tissue. Glucocorticoids are the main treatment for many inflammatory diseases, 
however, the majority of COPD patients are resistant to glucocorticoids, so a better 
understanding of the exact mechanism of glucocorticoid resistance in COPD patients 
and lung cancer is necessary in order to improve the effectiveness of steroids. 
Glucocorticoids act through glucocorticoid receptors that are located in the cytoplasm. 
GRs are phosphorylated, and this post-translational modification affects their binding 
and interaction with other proteins. In this thesis the expression of TTC-5, a stress 
responsive co-factor, and the total and the phosphorylated GR in the peripheral lung 
tissue of COPD patients were examined and compared with the expression in healthy 
patients. Results indicate that total GR and GR phosphorylated at S211 and S226 are 
expressed in A549 lung cancer cells as well as TTC5. Preliminary results also suggest 
that TTC5 and GR interact in these cells. Furthermore, as determined by 
immunohistochemistry, the total GR, GR phosphorylated on S211 and S226 as well as 
TTC5 are expressed in human lung tissues and in associated macrophages. Finally, we 
detected altered TTC5 expression that correlates with disease status. These results may 
contribute to our understanding of the underlying mechanisms of glucocorticoid 
resistance in COPD and in lung cancer. 
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1. Introduction 
Chronic obstructive pulmonary disease (COPD) is a considerable health problem all 
over the world. It is the fourth leading cause of death and expected to be the third by 
2020 (Petty, 2003). Moreover, 40-70% of patients with COPD, especially in the late 
stages, develop lung cancer (Metcalf et al, 2009).   
In the United Kingdom, COPD and lung cancer are common debilitating diseases and a 
major public heath challenge. The NHS (National Health Service) spends about £800 
million annually treating COPD. Moreover the cost of management of lung cancer is 
about £10,000 per patient (Health news 2014, Oxford University). 
 
1.1 Lung physiology 
1.1.1 Lung volumes and capacities  
Physiologically the lung is the place where respiration takes place and the function of 
the lungs is determined by volumes and capacities. Lung volumes reflect the amount of 
air that can be inhaled during different stages of the respiratory cycle. Several important 
definitions can be measured to estimate lung function as listed below and shown in 
figure 1. Tidal volume (TV) is the amount of air entering and exhaled during resting. 
Total lung capacity (TLC) is the amount of gases contained inside the lung at the end of 
maximum inspiration and it is the vital capacity plus residual volume (the amount of air 
that remains after full expiration). Vital capacity (V.C) is the amount of air that is 
expelled after deep inspiration. Residual volume (R.V) is the amount of air inside the 
lung after forced complete expiration. Forced vital capacity (FVC) is the amount of air 
that can be exhaled following full inspiration. Forced expiratory flow (FEF 25%-75%), 
measures the airflow at mid-point of expiratory phase. Functional residual capacity 
(FRC) is the volume of air left inside the lung after normal expiratory phase. Inspiratory 
reserve volume (IRV) is the volume of air that can be inhaled beyond normal 
inspiratory breathing. Expiratory reserve volume (ERV) is the air that can be exhaled 
beyond the normal expiratory phase. In addition, there are some terms which they are 
important in the alveolar ventilation-perfusion processes, such as physiological dead 
space which is part of tidal volume which is not involved in the O2-CO2 exchange 
process. Anatomical dead space is the amount of air inside the airways which does not 
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participate in the ventilation process and alveolar dead space, that represents the 
difference between anatomical dead space and physiological dead space, and this 
amount of air does not participate in gas exchange.  Figure 1 illustrates the important 
values in the lung (Becker et al, 2009). 
 
                                              
Figure1- Lung volumes and capacities. Lung volumes include (TV, IRV, ERV and 
Residual volume) and derived lung capacities including FRC, IC, VC and total lung 
capacity (Becker et al, 2009). 
 
In normal individuals the peak of lung performance is achieved by age of 20 and 25 
years among females and males respectively, followed by a plateau phase until the age 
of 35. Lung performance then gradually starts to decrease. This is shown in figure 2 
(Fletcher and Petos’s, 1977). 
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Figure 1-2. Age related decline in FEV1 in healthy individuals and COPD. FEV1 
decline in normal healthy individuals (first line) is slow and usually in normal people 
the rate of decline is unnoticeable even after age of 75. In regular smokers (Second 
line), the FEV1 decreases more rapidly and the rate of decline is directly proportionate 
to the comorbidity and the death rate at the age of 65 and 75 years respectively (Löfdahl 
et al, 1998). Modified Fletcher and Petos’s graph, (1977).    
 
A part of respiration is explained by the lung function, which is subdivided into three 
main categories based on spirometry, lung volumes dependant flow rates, which include 
forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and the 
ratio of FEV1/FVC. The second part of lung function cannot be determined by 
spirometry. It is known as static lung volumes comprise total lung capacity (TLC), vital 
capacity (VC), residual volume (RV), and functional residual capacity. Finally, the 
ability of blood gases to cross the alveolar blood barrier is measured by carbon 
monoxide diffusion capacity (CLCO). 
 
1.1.2 Factors that may affect lung volumes  
There are three factors affecting lung volumes and capacities. The first is height, 
because tall individuals have larger lungs, thus larger volumes and capacity. The second 
is body mass index. Obesity adversely affects lung volumes and capacity. The third is 
altitude. People who live at high altitude are more able to compensate for the low 
oxygen level by increased lung capacity.  
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1.1.3 Physiology of gas transport 
In dry air oxygen accounts for approximately 21% of air, and the Partial pressure of 
oxygen is about 160mmHg of total air pressure (760mmgh). Physiologically, the partial 
pressure of oxygen and carbon monoxide is the main determinant of the oxygenation 
process, in which PO2 and PCO2 inside the alveoli is about 100mm and 40mm Hg 
respectively. The opposite is the case in capillary blood vessels (figure 1-3). In addition, 
the amount of oxygen across the alveolar membrane into the capillary blood vessels is 
directly proportionate to the alveolar surface area and reciprocal to membrane thickness 
and determined by carbon monoxide diffusion capacity (DLCO) (Stamet et al, 1994). 
  
Figure 1-3 Gas exchange and partial pressure in the ventilation process. (A) O2-CO2 
exchange across the respiratory barrier showing pressure difference between the alveoli 
and the capillary blood vessels. (B) Higher partial pressure of oxygen (PO2) in the 
systemic capillary blood vessels facilitates its delivery into different parts of the body 
(Stamet et al, 1994). 
 
1.2 Defence system in the lung 
There are various environmental pollutants that may have a detrimental effect on lung 
function, such as carbon monoxide, which has a higher affinity to haemoglobin (210 
times higher than oxygen) (Ganong et al, 1995). However, the clearance system in the 
upper and lower respiratory zones are effective in eliminating the majority of deposited 
particles. 
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Two important mechanisms are well known as a first line of defence: the mucociliary 
system in the airways and alveolar macrophages in the air passages.  
 
1.2.1 Mucociliary System  
The mucociliary system is an important mechanism for protection from harmful 
organisms via ciliary movement and the mucus layer that is produced by Goblet cells 
(glandular simple columnar cells located in epithelial layer), and the mucus gland 
located in deep epidermis (Morgan et al, 1986). 
There are a number of related congenital diseases associated with abnormality in ciliary 
structure and function causing an impaired elimination of noxious particles and 
subsequently leading to chronic respiratory disorders such as primary ciliary dyskinesia 
(autosomal recessive genetic disorder) also known as immotile cilia syndrome 
characterized by malfunctioning cilia and chronic infections. In addition, patients with 
cystic fibrosis and Young's syndrome may develop immotile cilia syndrome (Afzelius et 
al, 1981).   
 
1.2.2 Lung macrophages  
Lung macrophages are the most important line of defence in the lower respiratory zone, 
and are considered part of the mononuclear phagocyte system and one of the front line 
defences in the lung. They develop as a result of migration of circulatory monocytes 
into the lungs (Cohn et al, 1968). Nevertheless, the monocytes do not enter the alveoli 
directly, they divide and gain bio-inflammatory characteristics then migrate to the 
alveoli (Bowden et al, 1976). Macrophages play a pivotal role in both innate and 
acquired immunity, either by direct phagocytosis of foreign antigens or by initiation of 
an inflammatory cascade by releasing a number of pro-inflammatory and anti-
inflammatory cytokines and chemokines. In some diseases like COPD, the phagocytic 
ability is disturbed by smoking, in addition it is suggested to play a role in tumour 
development (Mantovani et al, 2008). Four types of macrophages have been identified 
according to the site; alveolar macrophages, interstitial macrophages, intravascular and 
dendritic cells. Alveolar macrophages are the predominant type of this group and 
increase in number with the severity of COPD (Barnes et al, 2008). Because 
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macrophages are exposed to the environment, they have developed the ability to 
recognise and phagocyte the foreign particles, which may end by over-production of 
inflammatory cytokines and tissue remodelling factors triggering the inflammatory 
process and tissue repair. This type of cell is associated with tissue destruction in COPD 
through the release of inflammatory mediators including proteases such as 
methalloproteinases-1.The extent and severity of alveolar destruction (emphysema) is 
related to the number of macrophages in COPD patients (Tetley et al, 2005), and the 
macrophages are accumulated in areas where alveolar destruction exists (Barnes et al, 
2004). Macrophages, isolated from COPD smokers, exhibit less phagocytic activity 
against some bacteria such as Haemophilus influenza. 
Activated macrophages are also sub-divided into two groups, according to secretory 
mediator and their roles. The first type, classical activated macrophage or pro-
inflammatory macrophages (M1), possesses an anti-inflammatory and cytotoxic 
character that enable them to eliminate intra-cellular pathogens especially bacteria by 
producing a large quantity of lymphokines. The second type, which are capable of 
presenting the antigens and producing anti-inflammatory 
 
              Mediators related to M2 Toxic particles to the lung 
         Reactive oxygen species (ROS) 
and Reactive nitrogen species (RNS) 
Ozone, Radiation, Bleomycin and 
Cilica 
 
                          Proteases  Bleomycin, Endotoxins and Sulphur 
mustard 
   Bioactive  Lipids and Pro-
inflammatory     mediators(TNF-α, IL-
1β and chemokines) 
Ozone, silica and Sulphur mustard 
             Mediators related to M2  
                          IL-10 Ozone, Silica and Endotoxins 
                          IL-4 Radiation, Silica, Endotoxin and 
hyperoxia. 
                          IL-13 Endotoxin, hyperoxia and Asbestos. 
                          TGFβ Bleamycin, Radiation and Asbestos. 
Table 1.1 illustrates number of mediators released by M1 and M2 macrophages in 
response to variable environmental and toxic particles. (Laskin et al, 2011). 
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Mediators are known as activated type (M2) and show anti-inflammatory properties, 
and hence are involved in tissue repair and development of T-regulatory cells. However 
some inflammatory mediators like IL-10 are poorly presented (Martines and Gordon, 
2009). Classical type (M1) is responsible for pro-inflammatory cytokines release (IL-12 
and TNF-α) and in addition enhances Th-1 immunity (Hoeve et al, 2005).  
 
1.2.3 Epithelial surface 
During embryogenesis the epithelial surface is derived from the endoderm tubule 
(Morrisey et al, 2010). The airways in the human lung are supported by cartilage that 
extends to the small airways which are lined by the ciliated pseudo-stratified columnar 
epithelium and surrounded by mucus-secreting glands and blood vessels. Beneath the 
epithelial surface, basal cells are responsible for renewal of injured epithelial and other 
secretory cells (Hong et al, 2004). Airway epithelial cells are further sub-classified into 
two groups, ciliated epithelial mediates dispose of the foreign particles; mucus cells, 
which are responsible for mucus production as well as cellular differentiation and the 
production of inflammatory mediators, mediate inflammatory response (Puchelle et al, 
2006). There are many toxic particles inhaled mainly from cigarette smoking that result 
in alteration of epithelial cells. One of these disruptions entails epithelial cells being 
replaced by squamous cells, resulting in reduction of ciliated cells as well as hyperplasia 
of mucus secreting cells. These changes are associated with loss of surfactant producing 
cells (Clara cells). Additional new studies showed an inverse correlation between NF-
KB expression and impaired defective mechanism in epithelial cells. Moreover, direct 
contact of epithelial cells with toxic materials increases airway the epithelial 
permeability (figure 1.4) by down regulation of the junctional barrier (Heijin et al, 
2012). 
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Figure 1.4. Normal epithelium histological types and significance of bronchial 
epithelial   dysplasia. Healthy epithelial surface (black arrow) shows small tiny cilia and 
epithelial disruption (yellow arrow), sub-mucosal layer with small blood vessels (Heijin 
et al, 2012). 
 
Healthy airway epithelia are an essential requirement for the integrity and proper 
function of the respiratory tree. Recurrent exposure to irritants may have a disruptive 
effect on the epithelial surface, which is participating in remodelling during its recovery 
(Grainage et al, 2013). Moreover, an intact epithelial surface is an important functional 
and structural barrier against inhaled particles. Frequent contact with irritants and toxic 
compounds such as cigarette smoke may initiate an inflammatory cascade, causing 
disruption in epithelial integrity, followed by a repair process via epithelial cells leading 
to the proliferation and regeneration of pseudo-stratified cells. Remodelling can result at 
any step during the repair process, including squamous metaplasia, smooth muscle 
hypertrophy, sub-mucosal and goblet cell hypertrophy and fibrosis. 
There are many triggering factors involved in the disruption of the epithelial surface, 
including bacterial or viral infection, allergic reaction (asthma, cigarette smoke) and 
trauma. During the repair process, the reactive inflammation to antigens is the same, 
however, long term response to the irritants varies in different parts of the lung, 
according to the architecture, level of oxygen, abundance of surfactant and blood supply 
of the area. For example a disruption to alveolar capillary blood vessels leads to 
irregularity in the basement membrane and induces fibrosis by activation of fibroblasts. 
The role of the epithelial surface is also important in the pathogenesis of COPD and 
dysfunction of this barrier could cause bacterial colonization and infection in COPD 
patients. 
According to the shape and function of epithelial cells in the alveolar region, they are 
classified into, type I squamous cells, which represent about 90% of the total number of 
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the cells, and type II cuboidal cells, which are responsible for production of surfactant, 
which is responsible for decreased surface tension during the respiratory cycle. 
 
 
Figure 1.5 Gas exchange function of the alveolar region in the terminal respiratory unit. 
(a) Lining epithelial surface (b) illustrates gas exchange through alveolar lining cells 
and mucus production from sub-mucosal glands, in addition to the formation of the 
mucin layer (yellow line). (C) and (d) respectively represent the pseudo-stratified 
epithelial surface (red arrow) and the underlying mucosal structure (yellow bracket) 
http://www.nature.com/reprints/index.html 
  
1.3.4 Dendritic cells 
Dendritic cells are a group of mononuclear cells, which have the ability to identify and 
uptake pathogens (Henderson et al, 1997). They are found close to the epithelial lining 
surface and possess cytoplasmic branches to interact with the environment and to 
facilitate their interaction with PMN and to induce an acquired immune response 
(Iwasaki et al, 2007). Dendritic cells originally existed in bone marrow and circulate 
throughout the body in immature form. Dendritic cells present antigens to lymphocytes 
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in regional lymph nodes. There are 100 times fewer dendritic cells in the alveoli and 
small airways of COPD patients than in healthy individuals. Moreover, this type of cell 
returns to normal as soon as patients stop smoking (Rogers et al, 2008).  
 
CD-8 T lymphocytes 
CD8-T lymphocytes also have an essential role in the adaptive immune response to viral 
infections, and especially in respiratory syncytial viral infection and in disease 
progression. CD8-T- lymphocytes have been detected in both large and peripheral 
airways during inflammatory response (Kim et al, 2008). Compared with heathy 
smokers, the number of CD8-T lymphocytes are significantly increased, mainly in the 
wall of the small airways, and the number of CD8-T lymphocytes are increased with 
progression of the disease (Saetta et al, 1998). T -lymphocytes are antigen-presenting 
cells. They are activated by determining antigens. In COPD non-activated cells return to 
the circulation. In addition to the involvement in the inflammatory process in the release 
of inflammatory cytokines, the CD8 T-lymphocytes are related to disruption of the 
micro-vascular environment as a consequence of chemokines such as IL-8 and 
monocyte chemotactic protein-1, produced  by T-cells (Abbas et al, 2000). 
 
1.2.6 Natural killer cells 
This type of cells is related to innate immunity. Natural killer cells act in a non-specific 
manner and secrete variable inflammatory mediators such as IFN-ϒ, TNF- α and IL12, 
which are involved in activation of immune cells to kill viruses. However, these cells 
are less active in smokers than healthy individuals (Ferson et al, 1979) 
 
1.2.7 Neutrophils 
Unlike alveolar macrophages and dendritic cells, neutrophils are part of innate 
immunity and account for 3 to 19% of all cells. Neutrophils flow into inflammatory or 
injured places to destroy pathogenic microbes in response to inflammatory signals from 
epithelial cells or regional macrophages. Neutrophils produce a variety of enzymes, the 
nature of whose effect is controversial. For example neutrophil elastase may cause 
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alveolar destruction if not controlled properly. Neutrophils are observed in the epithelial 
layer and the number of the neutrophils is directly related to restriction in the airways 
and to the severity of the disease (Chua et al, 2006).  In addition, Neutrophils isolated 
from COPD patients respond less vigorously than normal to chemoattractants (Beeh et 
al, 2003). The speed of travel toward the presenting antigens is also affected by the 
disease, moreover the chemotactic property of neutrophils isolated from COPD patients 
is less responsive than normal to chemo-attractants. The number of neutrophils is nearly 
the same in both healthy smokers and smokers with COPD, however the phagocytic 
ability of the neutrophils is decreased in COPD patients. 
 
1.3 Alveoli 
Alveoli are where gas exchange takes place. The alveolar sacs are lined with two types 
of cells, type I pneumocytes represent the majority and are responsible mainly for gas 
exchange, while type II account for approximately 5% of the cells and are more 
resistant to damage and are mainly responsible for surfactant production that reduces 
surface tension. They also have the ability to repair injured type I pneumocytes. In 
addition, these cells are responsible for xenobiotic metabolism and facilitate trans-
epithelial movement of water. Type II pneumocytes are implicated in pathogenesis of 
chronic obstructive pulmonary disease via production of inflammatory cytokines and 
are responsible for fibroblast inhibition during pathogenesis in some diseases (Kotton et 
al, 2014). 
Surfactant is a mixture of phospholipids and proteins, surfactant synthesis and 
production can be affected by genetic disorders. Cigarette smoking may alter surfactant 
synthesis by increasing the neutrophil elastase activity, MMPs and proteolytic enzymes 
(Hogg et al, 2004). 
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Figure 1.6. Involvement of surfactant dysfunction in pathogenesis of COPD. Impaired 
surfactant results in impaired immunity and airway collapse, causing more resistance in 
the small airways. On the other hand, surfactant causes an increase in neutrophil 
elastase and in metalloproteinases. Moreover, surfactant may activate NF-KB, which in 
turn induces inflammation. Together with increased resistance, the airway inflammation 
ends in COPD (Hogg, et al 2004). 
 
In chronic obstructive pulmonary disease, the surfactant system is impaired due to 
frequent contact with noxious particles from cigarette smoking, resulting in a reduction 
of the total amount of the surfactant (figure 1.7) (Barnes et al, 2009). 
 
Figure 1.7 Cigarette smoke and noxious particles increase apoptosis and injury of 
alveolar cells type II. The direct effect of toxic materials from cigarette smoke on type II 
alveolar cells, leading to activation of macrophages, which subsequently enhance 
phagocytosis. Defective surfactant function may increase the activity of proteases and 
oxidative stress (Zhao et al, 2010).  
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1.4 Chronic inflammation 
Inflammation is the protective mechanism against injury. Acute inflammatory response 
is initiated by recruitment of leukocytes from the circulatory system, starting by leakage 
of polymorph nuclear cells, followed by monocytes, which transform into macrophages 
(Majno, 1975). Chronic inflammation is generally characterized by tissue infiltration 
with mono-nuclear cells, lymphocytes, and plasma cells and sometimes is associated 
with tissue destruction as a result of the direct effect of chemicals or from inflammatory 
mediators that are secreted from the recruited cells. At the same time, as a part of 
chronic inflammation, a countervailing process of repair is usually mediated by 
angiogenesis and fibrosis, whatever the end-result of repair: restoration of normal 
architecture or permanent fibrosis (Rennard et al, 1999). 
 
1.4.1 Classification of inflammatory lung diseases 
Inflammatory lung diseases are classified according to the site of inflammation. Firstly, 
airway diseases mainly affect the passages of the air like, for example, asthma (a disease 
of large airways), bronchitis and bronchiectasis (permanent destruction of air spaces 
distal to terminal bronchioles). Secondly, parenchyma diseases usually affect the 
architecture of the lung, leaving either permanent destruction or fibrosis (emphysema, 
interstitial lung disease). Additionally, some inflammatory diseases affect blood vessels 
either by blood clotting or by scarring. 
 
1.5 COPD 
Term COPD is an international abbreviation for chronic obstructive pulmonary disease. 
It is classified as a systemic disease because of the extra-pulmonary involvement of the 
heart and skeletal muscles (MacNee, 2013). The most frequent leading causes of COPD 
are tobacco smoking, genetic inheritance and the environment. It is the 4th most 
common cause of mortality and morbidity. It is estimated to affect 20-30% of smokers 
and has a prevalence of 10% of the population as a whole (Afonso et al, 2011). The 
course of the disease is usually progressive, and many factors determine the disease 
severity including FEV-1, inspiratory capacity, DL-CO, hypoxaemia, impaired exercise 
capacity, BMI (body mass index), hypercapnia, dyspnoea and health status. Death 
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among patients with mild COPD is usually attributed to lung cancer and cardio-vascular 
diseases, however, in the advanced stages, the causes of mortality are non-malignant in 
origin (Berry et al, 2010).  
 
1.5.1 Nature and structural feature 
The prominent characteristic feature of chronic obstructive pulmonary disease is the 
involvement of the mucociliary system accompanied by airway structural changes, and 
more evidently loss of elastic recoil which is the reason behind hyperinflation and 
tapering of CO2 (Saett et al, 2001). The progressive airflow limitation in COPD is due 
to two major pathological processes: chronic bronchitis and emphysema. 
 
1.5.2 Chronic bronchitis 
The term chronic bronchitis refers to inflammation in the surface lining of the airways, 
manifested as a chronic productive cough for three subsequent months of two 
consecutive years. The clinical implications for chronic bronchitis are increased mucus 
production by goblet cells, frequent exacerbation, and remodelling of the epithelial 
surface (Kim et al, 2013). The inflammatory series starts at the small airways (less than 
5 mm in diameter) and lung parenchyma causing physiological and clinical 
complication. The cellular changes in the airways start with mucosal infiltration of the 
airways by inflammatory cells (macrophages, neutrophils and CD8 T-lymphocytes) 
leading to epithelial disruption, smooth muscle hypertrophy and fibrosis in severe cases 
(Cosio et al, 2002). In turn, these inflammatory cells start the inflammatory process by 
releasing different inflammatory mediators such as TNF, interleukins, C-reactive 
protein and fibrinogen. Angiogenesis is another structural change resulting from 
activation of the hypoxia inducible factor that leads to an increase of VEGF 
transcription. Nevertheless, level of VEGF expression is decreased in emphysema that 
is induced by smoking. Emphysematous alveolar septa are avascular (low 
angiogenesis). 
Inflammatory lung diseases are characterized by the new formation of small blood 
vessels as a result of the narrowing of blood vessels (Siafakas et al, 2007). The 
remodelling process may be induced by inflammatory mediators such as interleukins or 
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growth factors such as vascular endothelial growth factor (VEGF). Furthermore, micro-
vascular remodelling in COPD may enhance the thickening of the airways, which 
contributes to the progression of the disease (Lieckens et al, 2001). Although the 
thickening is increased as the disease progresses, the microvasculature is reduced 
especially in patients with co-morbidity like lung cancer and right side heart 
complications (Soltani et al, 2009).    
 
Structural changes are varied according to the stage of the disease. In COPD, smoking 
is the main cause of the structural and cellular changes. In healthy smokers respiratory 
bronchiolitis (inflammation of small airways) is the pathological hallmark in young 
smokers and the structural changes usually occur along the respiratory system in healthy 
smokers (not established COPD) (Piqueras et al, 2001). The main changes observed in 
many studies are infiltration of lung parenchyma with macrophages and T- lymphocytes 
in the absence of alveolar destruction or fibrosis. Meanwhile, a disrupted epithelium has 
been identified in the membranous bronchioles. In smokers with established COPD, the 
inflammatory cascades occur predominantly in small airways, resulting in resistance in 
small airways of less than 2 mm which is the hallmark in COPD patients. In (1968), 
Hogg et al discovered that small airway resistance is 4 times normal among patients 
with mild COPD, while total lung capacity was nearly normal. Conversely, in moderate 
to severe cases, because the resistance in small airways increased the total lung 
capacity, was higher than normal. The second effect is morphological, which 
dramatically affects the lung performance because of physiological abnormalities in the 
small airways, including mucus plugging, inflammation and increased smooth muscle 
and fibrosis. One report from the national lung and heart institute revealed that a 50% 
reduction in the number of small airways is related to a two-fold increase in peripheral 
resistance in COPD patients (Hogg et al, 2004). Moreover, a number of pathological 
changes has been reported in epithelial airways, including goblet cells hyperplasia in the 
proximal region of the airways in both ex-smokers and current smokers, as well as 
squamous metaplasia in the proximal and distal parts. In addition, short cilia have been 
reported in COPD patients (Hessel et al, 2011). According to the global initiative for 
chronic obstructive pulmonary diseases, squamous metaplasia and mucus hyper-
secretion are characteristic of stages III and IV (Hogg et al, 2004). Additionally, 
squamous metaplasia is related to the number of cigarettes smoked per day. 46% of 
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smokers and only 23% of ex-smokers develop squamous hyperplasia. Furthermore, the 
extent of metaplasia is related to a decrease in the forced expiratory volume in 1 second 
(Araya et al, 2007).  
Peri-bronchial fibrosis in COPD is enhanced by interleukin 1-β, secreted by squamous 
metaplastic cells, which in turn enhance production of the transforming growth factor 
and fibrosis (Kolb et al, 2001). Peri-bronchial inflammation and fibrosis may cause the 
centrilobular type of emphysema, which is usually associated with FEV25 changes in 
Spirometry. Disruption may occur in lung parenchyma and is considered to be a 
consequence of inflammatory reactions (Petty et al, 1985).                                                                                                                                                              
The smooth muscle hyperplasia in patients with COPD is prominent in the small 
airways, however, compared to asthmatic patients it is less marked in COPD (Hogg et 
al, 2004). At cellular level, persistent contact with tobacco smoke causes lung 
inflammation, characterized by invasion of white blood cells into extracellular spaces of 
the lung, causing accumulation of inflammatory cells in the lung tissue. 
 
1.5.3 Emphysema 
Abnormal dilation of airspaces beyond the terminal bronchioles, associated with 
alveolar destruction, is usually caused by an imbalance between protease/anti-protease 
activities in the lung microenvironment (Snider et al, 1985). Emphysematous changes 
have many effects on lung physiology, with gas transfer more affected than FEV1 (Parr 
et al, 2004). Furthermore, the alveolar destruction is the pathological hallmark in 
emphysematous lungs and loss of alveolar attachment and elastic fibre are related to 
collapse of distal airways during the expiratory phase (Vlahovic et al, 1999). 
The inflammatory series starts at small airways and lung parenchyma, causing 
physiological and clinical complications. Moreover, the risk of bronchogenic carcinoma 
is 32 times higher in patients with bullous lung diseases (Ogawa et al, 1999). In practice 
the emphysematous lung is diagnosed by high resolution CT scan in addition to 
spirometry changes. Morphologically, emphysema is sub-classified into three types: 
centrilobular, pan-lobular and para-septal emphysema (Figure 1.8). 
Centriacinar is the most frequent type. It features dilatation of central parts of lung 
bronchioles. The alveolar sacs are usually not affected (Leopold et al, 1957). The upper 
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lobe is the most affected part. Furthermore, this type is predominantly related to 
cigarettes. In the early stages of centrilobular emphysema, the border between the inner 
affected area and the outer region is not well identified by a high resolution CT scan. 
Panacinar emphysema is less frequent than the centriacinar type, and the α1- antitrypsin 
is the commonest cause (Figure 1.8-C). The destructive dilatation of the affected areas 
in this type started from respiratory bronchioles up to the alveoli and lower parts are 
more affected than the upper zone (Heppleston et al, 1961). Panacinar emphysema is 
localized or diffuse in form, and the affected parts tend to be hypo-echoic in contrast to 
the normal lung. In addition, the borders of panacinar sacs are not well defined (Stern et 
al, 1994). 
Para septal emphysema is the least frequent type. The peripheral parts of acini are 
usually the affected site and the posterior surface of the upper parts of the lung is the 
predominant affected area. This type of emphysema in young age groups is usually 
asymptomatic, although the risk of pneumothorax is higher (Figure 1.8-C) 
Figure 1.8 High-resolution CT scan of the chest. (A) High-resolution CT scan of the 
chest shows ill-identified margin of emphysematous sacs (arrow) in mild 
emphysematous changes (early stages). (B) CT scan shows radiological appearance of 
diffuse form of panacinar emphysema with ill-defined border (between the brackets). 
(C) CT scan chest with para septal emphysema with sub pleural air spaces (arrows). 
(Masashi et al, 2008)      
 
1.5.3.1 Alpha1-antitrypsin deficiency 
Autosomal recessive disorder affects 1 in 3000 births per annum, and manifest in the 
liver and lung, including emphysema and chronic bronchitis. In emphysema about 90% 
of anti-trypsin activity is α1- antitrypsin. Malfunctioning or deficiency in α1- antitrypsin 
is a leading cause of emphysema. 
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Αlpha1-antitrypsin is an acute phase reactant secreted by hepatocytes. It is the major 
inhibitor of proteases such as neutrophil elastases and proteases (Anderson and Lomas, 
2006). In addition the most common genetic abnormality is linked mutation in SERPIN 
A1 gene. 
A genetic defect in the protein causes misfolding, which is referred as α1-antitrypsin Z 
(ATZ), and the accumulation of ATZ in the endoplasmic reticulum of hepatocytes has a 
proteotoxic effect on liver cells (Erikson et al, 1986), and causes fibrosis and cirrhosis 
and hence increases the risk of hepatocellular carcinoma. 
 
1.5.3.2 Emphysema in α1-antitrypsin deficiency: 
Emphysematous changes in alpha-1 antitrypsin deficiency are caused by protease-
antiprotease imbalance, inflammation, and mechanical damage. In a clinical setting the 
patients are usually asymptomatic in early life, however, affected patients develop their 
symptoms at third or fourth decade. Characteristic features of emphysema related to α1-
antitrypsin deficiency are panacinar and usually affect the upper lobe. The symptoms 
usually start at the fourth or fifth decade (Tomashefski et al, 2004) 
 
1.5.3.2 Neutrophil Elastase (NE) 
Neutrophil Elastase (NE), is a serine protease, whose molecular mass is 28000-31000 
g/mol (Sinha et al, 1987). It is produced by variety of cells, mainly neutrophils, and is 
inhibited by α1-antitrypsin. A deficiency in the lung tissue and an elevated elastase in 
the sputum are correlated with a decline in FEV1 (Betsuyaku et al, 2000). NE also 
increases expression of IL8 in pulmonary epithelial cells in cystic fibrosis patients. 
(Nakamura et al, 1992). Moreover, disruption of elastase causes emphysema by 
affecting the Elastin which is the cardinal part of the architecture of lung tissue. 
 
1.5.4 Blood vessels 
In severe cases of COPD, blood vessels, especially those smaller than 500 µm in 
diameter are usually affected by hypoxemia, causing more resistance. Recently it has 
been discovered that even in early stages of COPD, smooth muscle proliferation, elastin 
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and collagen deposition exist in the inner surface of small blood vessels. Moreover new 
small blood vessels are the pathological hallmark in COPD. Angiogenesis is strongly 
associated with bronchiectasis and asthma. As well as COPD and lung cancer, the 
angiogenesis of squamous dysplasia is considered as premalignant change 
(Caldenhoven et al, 2012). 
New growth of blood supply is known as angiogenesis, however, changes in 
morphology such as increasing the diameter without formation of new blood vessels is 
considered to be blood vessel remodelling. Hypoxia is responsible for new vessel 
formation in severe cases of COPD by upregulating VEGF (McDonald, Walsh and 
Pearson, 2001). Tumours in general are characterized by new vessel formation 
(angiogenesis) (Strieter et al, 2004). 
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                         Area affected 
 
        Pathological changes in COPD 
 
 
 
 Proximal airways ( >2mm in diameter)  
  .Number of macrophages and                             
CD8-T lymphocytes   
. Few neutrophils and eosinophils 
. Enlargement of sub-mucosal gland and 
goblet cell metaplasia. 
. Infiltration of mucus glands with 
lymphocytes and neutrophils   
Smooth muscle hypertrophy and 
squamous metaplasia of lining epithelium. 
 
 
 
 
Distal small airways(< 2mm in    diameter) 
 .  Macrophages and CD8 T-lymphocytes  
 .  B lymphocytes, lymphoid follicles and  
    Fibroblasts. 
 . Small number of neutrophils and      
eosinophils 
 . Evidence of bronchiolitis 
 . constriction and Peri-bronchial fibrosis 
 . squamous metaplasia of epithelial lining    
small airways  
 
                        
 Parenchymal tissue 
 .  CD8 T-lymphocytes and macrophages 
 . Destruction of alveolar wall  
 . Microscopic and gross enlargement of 
airspaces (emphysematous bullae). 
 .   
 
 
Pulmonary blood vessels 
    Total number of macrophages and  
    T-lymphocytes 
 .  Initial changes include intimal 
thickening and dysfunction 
 . delayed changes represented as 
hypertrophied smooth muscle and 
collagen deposition leading to pulmonary 
hypertension and cor-pulmonale 
Table 1.2 cellular and structural changes in COPD. Proximal and distal airway 
changes as well as cellular infiltration associated with COPD (William, 2006)  
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1.5.5 Spirometry changes 
Spirometry provides objective measures about the severity and reversibility of 
obstructive and restrictive disease (Figure 1.9). In addition, the quantitative data 
obtained by spirometry is important to confirm a diagnosis of COPD, and to measure 
the severity and progression estimation of the disease (Vestbo et al, 2012). A diagnosis 
of COPD is based primarily on reduced FEV1 to FVC ratio in addition to other 
parameters that have emerged as important predictors for small airways disease, like 
FEV25-75 (Marseglia et al, 2007). 
 
Figure 1.9 (A) Inflammatory and Spirometry changes in COPD. Parenchyma 
destruction in COPD patients. (B)Inner surface changes in the small airways showing 
disruption in the surface with mucus hyper-secretion. (C) Shape of the curve in normal 
heathy and COPD individuals. (D)Volume-time curve showing FEV1 in litres and 
expected FVC in 4 seconds (Vestbo et al, 2012). 
             
1.5.6 Classification and severity of COPD 
The global initiative for chronic obstructive lung disease (GOLD criteria) has launched 
criteria dependent on symptoms, spirometry changes and history of exacerbation in 
diagnosis of COPD. A bronchodilator test (percentage of change in FEV1 after 
bronchodilator nebulizer) is one of the most common tests to distinguish asthma from 
COPD in practice. A post bronchodilator measurement of FEV1 is usually negative in 
COPD patients. There are four categories of COPD: mild, moderate, severe and very 
sever. In mild COPD, symptoms are non-specific in the form of a cough, and 
FEV1/FVC<70%, FEV1≥80% is predicted. At this stage the patient is not aware of any 
symptoms. In moderate COPD FEV1/FVC<70%, FEV1 ≥ 50% and < 80% is predicted 
and the patient complains of progressive shortness of breath usually during exercise. 
Severe COPD is characterised by FEV1/FVC<70%, FEV1 ≥ 30% and <50% and the 
patient’s symptoms and exacerbations constrain his daily activity. In very severe cases, 
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the lung performance is markedly affected and FEV1/FVC<70%, FEV1<30% or FEV1 
less than 50%, usually accompanied by respiratory failure. In addition, the quality of 
life is affected at this stage. 
 
1.5.7 Physiological changes in COPD patients 
The most striking physiological abnormality in COPD patients is expiratory flow 
limitations, which occur as a consequence of alveolar destruction leading to air trapping 
and hyperinflation (Kainu et al, 2008). Moreover, during exercise the harmful effects of 
resting hyperinflation are exaggerated when the inspiratory demands are increased. 
Additionally, decreased expiratory timing leads to more air trapping, dynamic 
hyperinflation and increased mechanical restriction. Therefore inspiratory capacity, 
which reflects the end expiratory lung volume (EELF), is decreased as EELV (end 
expiratory lung volume) increase (Bikker et al, 2009). 
Airway and parenchymal inflammation in the majority of COPD patients are associated 
with a decrease in FEV1 and fibrosis in the long term (American Thoracic Society, 
2000). Furthermore, patients with established COPD have abundant macrophages 
compared with healthy smokers (Finkelstein et al, 1995). Tissue remodelling is a crucial 
pathophysiological change in COPD patients, which is characterized by abnormal repair 
of the epithelium and an accumulation of fibroblast cells, leading to fixed bronchial 
obstruction (Stockley et al, 2002). Moreover, frequent contact with harmful particles 
enhances inflammatory cells in the mucosa, sub-mucosa and glandular tissue, resulting 
in excessive secretion of mucus and thickening of small airways. 
The major cellular components of this process are neutrophils and macrophages, which 
are the prominent cells in the parenchymal tissue, bronco-alveolar lavage, and sputum. 
In addition, these cells are involved in tissue destruction and remodelling, and defence 
mechanism (Stockley et al, 2002). Moreover, relocation and activation of these 
inflammatory cells are regulated by cytokines and chemokines such as TNF-α, 
interferon -ϒ, interleukin- 1β and IL6 (Wouters et al, 2009). 
Tissue remodelling in COPD has two forms: thickening of the small airway, and 
alveolar destruction. It is presented, however, by mucus hyper-secretion and small 
airway fibrosis. Small airway remodelling in COPD patients affects the transition zone, 
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which lies between the airways and the alveoli. Alveoli show alveolar destruction and 
peri-bronchial fibrosis because of epithelial irregularity and hypertrophied smooth 
muscle. 
 
1.5.8 Alveolar hypoxia and hypoxemia in chronic obstructive pulmonary disease. 
The term “hypoxia” reflects a limited oxygen flux which causes oxygen deficiency to 
occur at tissue or cellular level. The term “hypoxemia”, on the other hand, refers to a 
reduction of the oxygen level in the arterial blood (haemoglobin saturation <92%, 
arterial oxygen pressure < 70% or alveolar arterial gradient > 25 mm gH). Oxygen 
enters the body without any effort at atmospheric pressure of 760 mm gH and this is 
more or less the pressure inside the lung. However when the process of respiration starts 
the negativity inside the alveoli increases, as a result of stretching the visceral pleura 
outside, which allows the air to come inside. The process of expiration differs and 
depends mainly on the elastic recoil of the lung parenchyma. Loss of this property may 
cause air trapping and hyperinflation observed in COPD (Incalzi et al, 2009) 
Oxygen is transported by capillary blood vessels in the lung tissue into different parts of 
the body through the heart and any defect in the blood vessel formation in the peripheral 
lung of COPD patients, for example a decrease in VEGF (vascular endothelial growth 
factor), may contribute to hypoxemia. 
The severity of the disease in both obstructive and restrictive lung diseases is related to 
the degree of alveolar hypoxia and hypoxemia (Han et al, 2006). As well as an increase 
in airflow limitations, the ventilation/perfusion mismatch increases, which may be 
aggravated by sleep and exercise (Rodriguez et al, 2009). The most determinant factor 
in the development of hypoxemia in COPD is ventilation/perfusion mismatch, which 
results from emphysematous destruction of the pulmonary blood vessels and airflow 
limitation. 
In COPD patients the ventilation/perfusion mismatch results in destruction of the 
capillary bed of the alveolar septa. Moreover frequent exacerbation is associated with 
deterioration in gas exchange and hypoxemia. Long-term disturbance in oxygen 
delivery may cause serious complications if the hypoxemia is not corrected, including 
systemic inflammation, pulmonary hypertension, muscle wasting and polycythaemia. 
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Long-term oxygen therapy (LTOT) can improve the quality of life, and hence is one of 
the options in the management of alveolar hypoxemia (Rabe et al, 2007). 
Systemic inflammation is one of the possible complications associated with COPD. 
Many factors are proportionally related to systemic inflammation in COPD. These 
include tobacco consumption, degree of hypoxemia and a narrowing of the airways (Sin 
et al, 2006) 
 
1.5.9 Complications 
COPD is a common cause of hospitalization among elderly patients and co-morbidities 
are a frequent cause of hospitalization. Coronary artery disease, diabetes mellitus, 
infections, osteoporosis, and muscle wasting are the most frequent complications. 
7-10% of COPD patients develop lung cancer (Mannino et al, 1993; Hansell 2003). 
Long-term complications are associated with cachexia (weight loss), which occurs in 
25-65% of cases associated with an increase in leptin level (adipose derived hormone). 
Leptin is considered as pro-inflammatory factor, which is involved in the release of 
other inflammatory factors like IL6 (Yang et al, 2006). 
 
1.5.10 Management of COPD 
Deterioration of lung performance in COPD starts slowly at the beginning and rapidly 
progresses with advancement of the disease. Nonetheless, smoking cessation remains 
the first and the most important way to halt further progression and reduction of FEV1.  
The pharmacological treatment depends on the clinical stages of the disease. In mild 
COPD (FEV1/FVC ≥70%), where breathlessness on exertion is the most common 
symptom, the mainstay of treatment is short acting β2-agonist which acts via 
stimulation of the cell surface of β2-adrenoreceptors (member of G-protein) (Jonson and 
Malcom, 1998), which in turn activate protein kinase-A by a sequence of reactions 
resulting in phosphorylation of the intracellular regulatory proteins, which then block 
histamine and cysteinyl-leukotrine efflux from mast cells; moreover β2-agonists possess 
an anti-inflammatory property. 
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Anti-cholinergic medication is another group that can alleviate bronchoconstriction via 
relaxation of smooth muscle by blocking the muscarinic receptors (Rabe et al. 2007). 
Inhaled corticosteroids are important in the management of COPD as they decrease 
hospital stay and reduce frequency of exacerbations. Nevertheless, the long-term benefit 
is not clear (Lung Health Study Group, 2000). 
 
1.5.11 Indication of steroids in management of COPD 
 
(Figure 1.12), Indication of glucocorticoids in management of COPD. Use of 
glucocorticoid is usually redistricted on mild cases, however during exacerbations 
steroids along with long acting β2 agonists are usually recommended.   
 
1.5.12 Oxidative stress in COPD 
Oxidative stress is a disturbed balance between oxidants, such as reactive oxygen 
species (ROS) and the anti-oxidant defence line (Betteridge, 2000). Three main sources 
of oxygen free radicals are smoking, inflammation and infections. Oxygen free radicals, 
which are responsible for alteration of oxidative stress, are released by inflammatory 
cells as a result of the consumption of oxygen (American Thoracic Society, 1996) 
(Figure 1.11). Oxidative stress is considered as the main explanation of pathogenesis of 
COPD. ). Both oxidative and nitrates stress are increased in COPD and are profoundly 
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increased with frequent exacerbation (Barnes et al, 2009). Oxidative stress is initiated 
by products of neutrophils and macrophages causing tissue damage and turns on nuclear 
factors such as NF-KB and activating protein-1 (AP-1), leading to production of pro-
inflammatory cytokines and chemokines. Meanwhile, frequent injuries or repeated 
infections could initiate inflammation. Antioxidants such as Nrf2 activator are inactive 
inside the cells until released by the effect of Nrf2 activators, then translocate into the 
nucleus to exert their effect by binding to anti-oxidant response elements (ARE) (Itoh et 
al, 2004). These anti-oxidants are markedly decreased in COPD patients because of 
cigarette smoking and frequent exacerbation (de Boer at el, 1989).  
 
(Figure 1.11). Role of Oxidative and nitrative stress in pathogenesis of COPD.                                                                                                                         
Different oxidant are involved in the activation of alveolar macrophages, neutrophils 
epithelial cells leading to production of ROS (reactive oxygen species) and RNS 
(reactive nitrogen species), as well as activation of redox sensitive transcription factors. 
They might have a role in inflammatory cascade responsible for COPD. 
 
1.5.13 Role of inflammatory mediators in COPD 
In heathy people the respiratory zone is sterile, however bacteria have been identified in 
patients with established COPD. In addition, the presence of bacteria in the lower 
airways is involved in the pathogenesis of the disease by releasing inflammatory 
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mediators that cause epithelial destruction and mucus overproduction (Grainge et al, 
2013). 
There are several inflammatory cytokines and chemokines (more than 50 different types 
of inflammatory mediators) involved in the inflammatory process in COPD patients 
(Table 1.3). Cytokines have been categorized into four main groups: 1) lymphocytes 
(cytokines which are released by T-cells and involved in the inflammatory process), 2) 
pro-inflammatory cytokines (enhance inflammation), 3) growth factors (cytokines that 
are responsible for structural modification which enhance the proliferation, 
differentiation and survival of cells), and 4) chemokines. Chemokines are inflammatory 
cytokines, which possess a chemotactic property for inflammatory cells and enhance the 
inflammatory process.  
The most important pro-inflammatory cytokines involved in COPD are TNFα, IL-1β 
and IL6, in addition IFN-ϒ. 
  
39 
 
Table 1.3 Cytokines netwok in Asthma and COPD (Barnes, 2008). Different 
inflammatory mediators are involved in the pathogenesis of COPD, involving 
lymphokines and T-cell regulatory cytokines, pro-inflammatory cytokines, anti-
inflamatory cytokines, growth factors and chemokines 
 
Cytokines are extra-cellular signalling proteins with relatively low molecular weight. 
They are produced by variety of cells and implicated in cellular interactions. In addition, 
inflammatory cytokines have a paracrine effect (on the neighbouring cells), an 
endocrine effect (at distance) and influence the original cells that secrete the cytokine. 
Both cytokines and chemokines act by binding to transmembrane receptors and the 
effect may be overlapped in a synergistic or antagonistic way by other cytokines 
produced by the same cells. TNF-α is one of the most important inflammatory 
 
Cytokines 
  
Role in COPD 
Lmphokines and T-cell 
regulatory cytokines                
IL4    
IL5 
IL9 
IL12 
IL13   
IL17    
IL25 
IFN-ϒ 
 
 
Unknown 
Unknown 
Unknown 
Inhances the disease 
Reduce the inflammation 
Enhances the disease 
Unknown 
Enhances the disease 
Pro-inflammatory 
cytokines 
IL-1β, IL-6, TNF-α  
 
  Enhances the disease. 
Anti-inflammatory 
cytokines 
IL-10 
 
Reduces the inflammation 
Growth factors 
TGF-β 
VEGF 
 
Increase in the disease. 
Increase in the disease. 
Chemokines 
(CCR2,3,4,5 agonists) 
Enhances the disease except CCR4 agonist 
Unknown.  
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mediators associated with systemic manifestation, such as muscle weakness and wasting 
in chronic obstructive pulmonary disease (Wouters, 2002) and has been found over-
expressed in patients with emphysema.  
 
1.5.13.1 Role of Interleukin-6 in health and disease 
IL6 is a multifunctional pro-inflammatory and immune-modulator cytokine produced by 
a variety of cells, such as epithelial cells, interstitial fibroblasts, macrophages and other 
inflammatory cells in response to cigarette smoking (Figure 1.10). IL6 is involved in 
inflammatory and immunological response, as it plays an important role in cellular 
proliferation and the survival of interstitial fibroblasts, thereby being involved in 
fibrosis. In addition, some studies show a high expression of IL6 in epithelial derived 
tumours (Grivennikov and Sergei, 2008). In lung tissue, it is mainly produced by 
alveolar macrophages and epithelial cells. Furthermore, one longitudinal study showed 
a relation between increased interleukin 6 in the sputum of COPD patients and 
deterioration in FEV1, exacerbation and pulmonary infections (Hagashimoto et al, 
2009).  
IL6 is implicated in the progression of the disease (Cosio et al, 2009). In addition, IL6 
secretion in COPD patients is directly proportionate to C-reactive protein level during 
exacerbations (Kolsum et al, 2009). High levels of IL6 in COPD patients are related to 
depression and increased mortality rate (Cavaillès et al, 2012), and concomitant 
cardiovascular co-morbidities (Cosio et al, 2009). The cytokine IL6 has both pro-
inflammatory and anti-inflammatory characteristics. The anti-inflammatory property is 
mediated by classic signalling, however, the majority of cells mediate the pro-
inflammatory. IL6 is located on chromosome 7P 21, and it is relatively small molecular 
weight protein (21kDa). IL6 attaches to cell member receptors, consequently leading to 
activation of JAF family of tyrosine kinase, which in turn stimulates pathways such as 
MAPKs, PI3Ks and others (Hodge et al, 2005). 
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Figure 1.10 Interaction of cells and cytokines in the airway inflammation of COPD. The 
effect of environmental and infectious agents (viruses) on epithelial cells, as well as the 
effect of different inflammatory mediators on macrophages eg TNF-α and on 
neutrophils eg.IL6, IL-8, MCP and its involvement in tissue damage (Chung, 2001). 
 
1.5.14 Future directions towards the new treatment of COPD 
New treatment options based on the cellular and molecular mechanisms are a point of 
interest for many inflammatory diseases like rheumatoid arthritis and COPD. The new 
drugs focus on the inflammatory mediators that are responsible for the activation and 
recruitment of the inflammatory cells and for the ROS (reactive oxygen species) that 
contributes to COPD (Barnes, 2011).  
TNF-α is elevated in the sputum of COPD patients. Moreover, TNF-α induces IL8 by 
enhancing transcription of NF-KB (Cheirakul et al, 2005). Anti-inflammatory drugs like 
phosphodiesterase inhibitors and P38 MAP kinase inhibitors are inhibitors of TNF-
expression. Moreover, phosphodiasterase-4 inhibitors block expressed 
phosphodiesterase in the inflammatory cells suggesting a potential effect in control of 
the inflammation (Edelson et al, 2001). 
Based on oxidative stress, which is increased in COPD patients (Nadeem et al, 2005), 
the anti-oxidants like N-acetyl cysteine have emerged, which show an anti-oxidant 
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effect both in vitro and in vivo. Recently, NAC (N-acetyl cysteine) was suggested to 
minimize the frequency of exacerbations (Gerrits et al, 2003).  
 
1.6 Steroids in health and disease  
Steroid hormones have an important role in the development, differentiation and 
homeostasis of the human body. Five classes of steroids are synthesized and released in 
organized rhythm (androgens, estrogens, progestin, mineralocorticoids and 
glucocorticoids), and each class exerts its effect by binding to a selected member out of 
48 members of the steroid nuclear superfamily of intracellular proteins. Synthetic 
glucocorticoids are more potent than naturally-released glucocorticoids (Piemonti et al, 
1999). Nuclear hormone receptors involve a superfamily of ligand dependent 
transcriptional factors that have role in wide cellular processes such as apoptosis, cell 
growth, development, differentiation and homeostasis. Many physiological processes 
including metabolism and haemostasis are influenced by nuclear receptors. There are 
two types of nuclear hormone receptors. Type I facilitate the effect of glucocorticoids 
(glucocorticoid receptors, GR), oestrogens (oestrogen receptors ER), mineralocorticoids 
(mineralocorticoid receptors, MR), progestin (progestin receptors, PR) and androgens 
(androgen receptors). Type II mediate the effect of thyroid hormones, 9-cis retinoic acid 
and vitamin-D. All nuclear receptors have same modular structure, consisting of N-
terminal A/B domain, DNA binding C domain and D, E, F (LBD) Carson et al, (1990); 
Mc kenna et al, (1999). 
There is evidence that glucocorticoid hormones are produced from various organs 
(Davis and Eleanor, 2003), however the adrenal cortex is the main site of synthesis and 
production of both glucocorticoids and mineralocorticoids. Under the control of the 
hypothalamic-pituitary axis various stress factors and hormones are responsible for tight 
regulation of glucocorticoid synthesis and production. Glucocorticoid production is 
enhanced by the adrenocorticotropic hormone from the pituitary gland, which is 
secreted under the influence of a corticotropin-releasing hormone from the 
hypothalamus. Mineralocorticoids are another important hormone similar to 
glucocorticoids and mainly responsible for reabsorption of sodium and water by the 
epithelial surface of collecting ducts in kidneys, salivary gland and large intestine 
(Schambelan and Morris, 1981). 
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The availability of natural glucocorticoids in tissues is regulated by corticosteroid-
binding globuline in serum and by locally expressed 11β hydroxysteroid dehydrogenase 
enzymes (11β-HSD). Essentially, the majority of tissues are expressing glucocorticoid 
receptors and their effect has a crucial influence on maintaining cellular functions and 
mediating pathological conditions (Figure 1.13). 
In the central nervous system, over-expressed glucocorticoid receptors are linked to 
depression and post-traumatic stress. Several experiments show a strong association 
between glucocorticoid signals and anxiety disorders. In addition, glucocorticoids have 
a critical role in maintaining immunity and suppressing inflammatory reactions 
following organ transplants. Furthermore, glucocorticoids increase the phagocytic 
ability of macrophages (Busillo et al 2011). 
 
Figure 1. 13| Effect of glucocorticoids on cellular and body function. Different tissue 
and organs are affected by glucocorticoids, including blood glucose, endothelial tissue, 
lipid metabolism and homeostasis.   
             
1.6.1 Glucocorticoids homeostasis 
Cortisol is the main type of steroid, and is regulated by the hypothalamic pituitary axis 
under the influence of the neuroendocrine system. Furthermore, the magnitude and 
duration of HPA activation is controlled by glucocorticoids (Keller et al, 1984).    
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Glucocorticoids are produced in a circadian manner with diurnal variation (Rose et al, 
1971). They have a diverse physiological effect on the majority of mammalian cells. 
Moreover, during some physiological conditions like stress and starvation, 
glucocorticoids stimulate the liver to replace the deficit by glycogenolysis and 
gluconeogenesis. Cushing's and Addison’s diseases result from a surplus and deficiency 
of glucocorticoid supply respectively. 
 
1.6.2 Response to steroids  
Endogenous glucocorticoid hormones are considered to be stress related hormones 
released under hypothalamic control. As a response to the hypothalamic factor, 
corticotropin-releasing hormones enhance the release of adrenocorticotropic hormones 
(ACTH) from the pituitary gland, and consequently ACTH induces glucocorticoid 
synthesis from the zona fasciculate in the adrenal cortex. Glucocorticoids are lipophilic 
and circulate in the blood stream attached to corticosteroid binding protein (GBP) 
(Wallimann and Peter, 1997). The therapeutic efficacy of glucocorticoid is either 
mediated by trans-repression, which largely mediates the anti-inflammatory property, or 
by transactivation, which is responsible for side effects. Generally the genes that have 
anti-inflammatory functions are induced by GR through its transcriptional activity, for 
example lipocortin, IL10 and IL1 receptor antagonist. Conversely the pro-inflammatory 
proteins that are responsible for induction of the inflammatory process are controlled by 
NF-KB and AP-1, and the role of glucocorticoids in this situation is trans-repressive by 
blocking pro-inflammatory genes. 
Glucocorticoid hormones enter the cell to interact with glucocorticoid receptors causing 
the release of heat shock protein (Pratt and William 1997). There are two types of 
glucocorticoid receptors both of which act as pro-inflammatory: GR-α which has 
agonistic activity and is related to glucocorticoid sensitivity, and GR-β that is related to 
insensitivity to the glucocorticoids. The complex then translocate into the nucleus and 
binds to the glucocorticoid response element (GRE) on responsive genes leading to 
increased or decrease transcription (Barnes et al, 2009). The GR gene is found on 
chromosome 5 (Hollenberg and Stanley, 1985). The GR function is controlled at 
multiple levels, by binding to hormones, nuclear translocation, interaction with 
cofactors and post-translational modifications such as phosphorylation and acetylation. 
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Four functional domains have been identified (Giguere and Vincent, 1986): N-terminal 
domain contains AF1 function that mediates transactivation of target genes. DNA 
binding domain (DBD) is involved in binding to GREs and contains two zinc fingers. 
The first involves AF1 which plays a role in trans-repression. The second finger has a 
role in dimerization of the receptor and the trans-activation that is mediated by the 
glucocorticoid response element. LBD (ligand binding domain) has a steroid binding 
function, a nuclear localization signal and ligand dependent trans-activation region 
which may interact with a co-activator or a co-repressor. The interaction between 
activated glucocorticoid receptors and GRE is considered to be classical and leads to 
activation of transcription, whereas binding with NF-KB is non-classical and is usually 
associated with transcriptional repression.  The actions of NF-KB are inhibited by GR 
through multiple mechanisms (Auphan et al, 1995). 
NF-KB is usually located in the cytosol in inactive state, bound with blocking proteins 
such as Ik B-α. Upon inflammatory signal. The NF-KB inhibitor-α is phosphorylated 
causing the release of NF-KB, which in turn translocate into the nucleus to interact with 
KB response elements and to regulate the genes coding the cytokines and chemokines to 
fight infection or inflammatory particles. Moreover, the imbalance or over expression in 
NF-KB may cause chronic inflammation (Ghosh et al, 1998).  
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              Systemic effect                      Local effect 
Lung Decreased macrophages 
in sputum 
Decease oxidative stress 
 Reduce eosinophils in 
sputum 
Reduction in mast cells 
  Down regulate synthesis and 
release of IL6 and IL8 from 
epithelial cells 
Circulatory         
system 
 Decrease CRP level 
 
Clinical 
 
Improved FEV1, shorter 
hospital stay, and improve 
the acute exacerbations 
Decrease hyper-
responsiveness of the 
airways, reduce exacerbation 
and slight effect on the rate 
of decline in FEV1 
 
 
 Improve cough and decrease 
sputum,  
Improve post Broncho-
dilator test in acute 
exacerbation and reduce 
mortality rate  
Table 1.4 Systemic and local effect of glucocorticoids (Barnes et al, 2011)  
 
1.6.3 Glucocorticoid receptor phosphorylation 
Glucocorticoid receptors are phosphoproteins that exist in most human cells. Although 
the glucocorticoid response is mainly determined by hormones, phosphorylation status 
also affects GR actions. Moreover, cellular conditions that affect phosphorylation of 
glucocorticoid receptors can have impact on GR transcriptional output. The most 
common sites for GR phosphorylation are serine 203, 211, 226 and 404. Moreover, 
glucocorticoid receptors have ability of phosphorylation at other sites of serine and 
threonine as well as tyrosine residues (Rao et al, 1987). Dephoure et al (2008) has 
suggested that other phosphorylation sites including threonine 8, serine 45, 134, 234 and 
267 exist. 
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Several residues within GR, for example S211, need phosphorylation to acquire full 
transcriptional activity (Krstic et al, 1997). S211 (phosphorylated glucocorticoid 
receptors at serine 211) use CDK and P38 kinases pathways, which is transcriptionally 
active as a result of conformational changes which mediate the recruitment of GR to 
GRE-containing promotor.  The JNK pathway is responsible for S226 (phosphorylated 
glucocorticoid receptor at serine 226) phosphorylation. This type of phosphorylation 
results in inhibition of GR activity, possibly because of increase in GR nuclear export. 
GR undergoes ligand-dependant self-regulation, which limits hormone responsiveness 
(Wallace et al, 2001). In addition, glucocorticoid sensitivity depends on availability of 
GR inside the cells. This process is also regulated by phosphorylation, in addition to 
transcriptional activity and nucleo-cytoplasmic localisation (Ismaili and Garabedian, 
2004). In previous studies p38 MAPK was found active in alveolar macrophages in 
steroid-resistant asthma (Bhavsar et al., 2008).  In response to external factors, MAPKs 
can affect cell behaviour and other biological processes such as migration, proliferation, 
and cell death. (Davis et al, 2003). 
                                                                       
Figure 1, 14| Phosphorylation of glucocorticoid receptor. GR modulates 
hormone signalling. Upon binding to glucocorticoids it translocates into the 
nucleus and starts transcription. In addition half the life of the protein may be 
altered by the phosphorylation (Galliher et al; Amy et al, 2009). 
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1.6.4 Underlying mechanism of glucocorticoids action in COPD  
A combination of long acting beta agonist and glucocorticoids has little effect on FEV1 
decline rate, however long-acting beta agonist and inhaled steroids diminish the rate of 
exacerbations and the severity of the disease (Mahler, 1999: Dahl, 2001).   
Down-regulation of inflammatory cytokines by HDAC2 in the presence of 
corticosteroids is a rational explanation for the therapeutic effect of glucocorticoids. 
Many clinical studies show that local and systemic glucocorticoids have an inhibitory 
effect on inflammatory cytokines (Lto et al, 2005). Moreover, Sin et al, (2006) 
conducted a study that showed that C-reactive protein levels are reduced in patients 
treated with glucocorticoids compared with placebo. 
In stable COPD patients, systemic glucocorticoids have no obvious effect on FEV1 and 
FVC (Walter et al, 2005). Moreover, glucocorticoids increase the mortality rate among 
COPD patients above 65 (Sin et al, 2001). There are other side effects of 
glucocorticoids, such as hyperglycaemia, hypertension etc. On the other hand, during 
acute exacerbation of COPD, glucocorticoids improve FEV1, decrease hospital stay and 
reduce the frequency of exacerbation.  
Inhaler glucocorticoids are involved in the management of COPD, however the exact 
causal mechanism of the benefit is still unclear. Pauwels et al (2001), carried out three 
years observational study on mild COPD patients who received inhaler glucocorticoids 
or placebo. The author concluded that there were no significant differences in FEV1 
decline rate. 
In COPD patients, prolonged use of glucocorticoids is responsible for systemic side 
effects and toxicity, including disturbance of blood sugar, increased risk of fracture, 
adrenal gland insufficiency (Walter et al, 2005), muscle weakness and depression 
(Decramer et al, 1994). However, there are some advantages including less hospital 
admission, fewer exacerbations and enhanced bronchodilator efficacy. (Scanlon et al, 
2000). 
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1.6.5 Mitochondrial GR 
GR translocation to the nucleus happen both in sensitive and resistant to glucocorticoid 
cells, while only in steroid-sensitive cells, glucocorticoid can translocate into the 
mitochondria. Mitochondrial membrane is directly affected by glucocorticoid 
hormones, resulting in loss of mitochondrial trans-membrane potential, hence disturbing 
the cellular processes mediated by function of mitochondria, for example ATP 
generation via oxidative phosphorylation, calcium flux and apoptosis 
             
1.6.6 Role of co-factor TTC5 in glucocorticoid action  
Nuclear hormone receptor function is controlled by numerous cofactors. GR also 
interacts with both coactivators, such as p300 histone acetyl transferase and 
corepressors such as histone deacetylases. One of the cofactors recently identified to 
affect GR is TTC5 (tetratricopeptide repeat domain 5). TTC5 is a cofactor protein 
originally identified in P53 response. TTC5 is a chaperone-like protein that mainly 
facilitates the assembly of multiple protein complexes. 
TPR motifs are protein-protein interaction modules, identified in a variety of proteins 
and usually in combination with other structural motifs (Blatch and Lassle, 1999). 
Demonacos et al (2001) have identified a stress responsive activator of P300 (STRAP, 
also known as TTC5) as a co-factor for P300 co-activator complex. TTC5 expression 
was significant in lungs, brain, and kidney mouse tissues and several cell lines. TTC5 is 
composed of six TPR motifs and is phosphorylated and regulated by DNA damage 
responsive kinases (Figure 15). 
TTC5 plays a pivotal role in P53 transcriptional activity in response to DNA damage 
and it is required to assist the interaction between JMY (transcriptional cofactor of P53) 
and P300 which in turn enhances apoptosis and P53 dependent transcription and 
prevents its degradation by MDM2 (negative regulator of p53 suppressor gene) (Coutts 
and La Thangue, 2006). HSP (heat shock protein) can also induce TTC5 to act as a co-
factor to enhance the transcription of heat shock genes during heat shock response 
(Davis et al, 2011) 
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Figure-1. 15 Structure of TTC5. (A) Domain organization revealing mapped interaction 
for JMY, P300 phosphorylation sites (Demonacos, 2001). (B) Ribbon diagram for 
TTC5 with coloured structure as in A. 
 
Stability, post-translational modifications and recruitment of co-factors are the main 
factors affecting glucocorticoid receptors. Post-translational modification is vital for GR 
transcriptional activity, stability and GR binding to other factors, suggesting that 
glucocorticoid hormone efficacy is highly dependent on post-translational 
modifications. Previous studies have shown a relation between GR and the TTC5/stress-
responsive activator of P300, in which activity and ligand-dependent down-regulation 
of GR is affected by TTC5 (Demonacos et al, 2011). Phosphorylation of the 
glucocorticoid receptor at some sites, like serine 211, is up-regulated after exposure to 
dexamethasone hormone, however interaction between phosphorylated glucocorticoid 
receptor and TTC5 is still under investigation. 
 
1.6.7 Complications associated with glucocorticoid treatments 
Long-term treatment with glucocorticoids is associated with undesirable side effects and 
complications involving many parts of the body, and these complications could be 
immediate or long term complications, which usually result as a consequence of a 
cumulative dose of glucocorticoids (Figure 14). The average doses of different types of 
synthetic glucocorticoids are shown in table 4. 
Increased weight and redistribution of fat is the most common long-term complication 
associated with glucocorticoids. One study, carried out for patients with rheumatoid 
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arthritis, has shown a 4 to 8% increase in BMI (Da silva et al, 2006). Another 
observational study concluded about 40% of patients above the age of 60 on 
glucocorticoids are at risk of osteoporosis and fracture, moreover, glucocorticoids can 
halt osteoblast activity responsible for bone formation in osteoporosis and cause 
pathological fracture (Canalis et al, 2004). 
Glucocorticoids may block the pro-inflammatory cytokines, leading to decreased 
macrophage activity and increased risk of infection. There is a very weak correlation 
between glucocorticoid use and the risk of peptic ulcer, however patients on steroid 
treatments with NSAID (non-steroidal anti-inflammatory drugs) are at four times 
greater risk of peptic ulcer than patients who are taking NSAID alone (Weil et al, 2000). 
More serious complications, such as osteonecrosis, can occur. Shigemura and Tomonori 
(2011) revealed taking 10mg/day of prednisolone for six months can increase the risk of 
osteonecrosis by 4 to 5%. Other serious complications of frequent use of 
glucocorticoids include hyperglycaemia and secondary diabetes, ischemic heart 
diseases, which are the major drawback to the use of steroids in high risk patients. 
Moreover, hypothalamic-pituitary adrenal axis suppression may develop over a long 
period. In the case of small cell lung cancer there is synthesis of pro-hormone ACTH-
like hormone, which is the same in character as that secreted by the pituitary gland. 
Negative feedback is responsible for blocking the expression and release of ACTH from 
the pituitary gland, nevertheless, in small cell lung cancer, glucocorticoids do not have 
the ability to block glucocorticoid release (Schlossmacher et al, 2003). 
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Figure 1.16| Side effect and complication from prolonged use of steroid hormones 
 
             Generic name of synthetic   
Glucocorticoids 
              Recommended dose/Kg/day 
Hydrocortisone 4 mg/kg/day 
Prednisolone 1 mg/kg/day 
Methyl prednisolone 0.8 mg/kg/day 
Dexamethasone 0.15-0.3 mg/kg/day 
Betamethasone  0.12 mg/kg/day 
Table 1.5 Types of synthetic glucocorticoids and recommended doses/Kg/day (Adapted 
from Gensler et al, 2013).  
 
1.6.8 Immunohistochemistry 
Immunohistochemistry is a common procedure used to identify the surface area and 
distribution of specific tissue antigens, and in situ detection by monoclonal and 
polyclonal antibodies. IGg is the most popular immunoglobulin used.   
The idea of immunohistochemistry started when Marrack, who invented reagents acting 
against cholera and typhus, based on a red-stain called tetraedro. In the 1940s, antigens 
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against streptococcus pneumonia were identified by fleuressin stain under ultra-violet 
light fluorescence microscopy (Coons et al, 1991). In the following years, Nakane 
introduced the idea of enzymes as a marker antibody (Avrameas et al, 1966; Nakane et 
al, 1968). 
 
1.6.7 Background of immunohistochemistry 
Immunoglobulin is Y in shape and has two identical heavy and white chains. The type 
of antibody is determined by the weight of the chain: heavy or light. Each one has two 
forms: lambda and kappa (figure 1.7). 
Fab portion is part of immunoglobulin that can bind to the antigen, which contains 
different segments of heavy and light chain and plays a role in stabilizing the antibody 
binding to the tissues. 
The FC region (the tail of immunoglobulin) is an important region, which allows 
binding of antibodies by FC receptors to inflammatory cells. Moreover, this part is 
important for non-specific staining in the technique. 
Paratop is the antigen-binding site of the antibody. The site of the antigen that binds to 
the antibody is known as “the epitope”. 
                                                      
Figure 1.17|. Structure of immunoglobulin. Fab Fragment (antigen binding).                                                                                                        
Fc Fragment, crystalized. CL constant domain (Light chain). Variable domain                                                                                                                  
heavy chain, and hinge region. http://www.ebioscience.com/knowledge-
center/antigen/immunoglobulin/structure.htm. 
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Previous researchers hypothesized that lung macrophages in COPD are resistant to 
glucocorticoids. Plumb et al (2013) conducted research about phosphorylated GR in 
peripheral lung tissue, concluding that phosphorylated GR (S211 and S226) are 
expressed in lung macrophages in heathy and COPD patients. On the other hand, 
phosphorylated forms of GR (S211 and S203) were expressed in the lung epithelial 
surface, but the form of the GR phosphorylated at S226 was not expressed. Moreover, 
the phosphorylation status of glucocorticoids in lung macrophages was not affected by 
the disease as high degree phosphorylation in lung macrophages was detected. 
The conclusion from previous research indicated that there were abundant 
phosphorylated forms of GR in lung macrophages, suggesting that this process was not 
disrupted in COPD patients (Adcock et al, 2005). In addition, optimum concentration of 
17-BMP at small airways of COPD patients is enough to suppress pro-inflammatory 
mediator production by macrophages (Plumb et al, 2013). 
 
1.7 Lung cancer 
Lung cancer is the fourth most common cause of death in the world and about 41,000 
cases are diagnosed every year in the UK. According to its histopathological features, 
lung cancer is classified into two types: small cell and non-small cell.  
Non-small cell lung cancer accounts for approximately 85% of cases. Three types of 
lung cancer belong to this group: squamous cell carcinoma, large cell carcinoma and 
adenocarcinoma. About 40% are adenocarcinomas and usually occur in peripheral areas 
of the lung tissue, while squamous cell carcinoma usually occurs in central areas and 
more frequently in males than in females. This last detail is related to smoking patterns 
across sexes (Minna et al, 2008). Response to treatment and disease metastasis is varied 
from one type to another. Small cell lung cancer usually responds poorly to treatment 
and spreads quickly. Moreover, surgical intervention is inadvisable. However, non-
small cell lung cancer responds better response to treatment. It is likewise subdivided 
into three main types: squamous cell carcinoma, adenocarcinoma and large cell 
carcinoma. 
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Adenocarcinoma is the most common type, and in the majority of cases the tumour is 
locally advanced or already metastatic at the time of diagnosis, with only 15% survival 
rate in 5 years. 
 
1.7.1 Histological features of non-small cell adenocarcinoma 
Non-small cell adenocarcinoma is subdivided into six groups according by histological 
features and clinical behaviour. Type A, known as local bronchoalveolar carcinoma, is 
solitary and grows by substituting the alveolar lining cells with a thickening of the 
alveolar septa. Usually there is no fibrotic foci with an unclear boundary. Type B, or 
localized bronchoalveolar type, is usually associated with foci and alveolar destruction. 
Its general microscopic appearance is the same as type A’s, however there are some 
alveolar foci that develop as a consequence of alveolar collapse. Type C, or localized 
bronchoalveolar with foci of active fibroblastic proliferation, is the most common 
histological subtype. The lining epithelium is replaced with active fibroblastic 
proliferation and small vessels are obvious. However, there are no active fibroblasts in 
the foci as with type B. Type D, or poorly differentiated adenocarcinoma, is 
characterized by a solid tumour, which is similar to large cell carcinoma. Moreover, it 
has clear boundaries between the tumour and the normal parenchyma. Type E, or 
tubular adenocarcinoma, is comprised of tubular and acinar structures. Tumour margins 
are well defined. Type F, or papillary adenocarcinoma type of tumour, grows by 
replacing the alveolar lining cells. Additionally, it shows destruction of the septa. 
 
1.7.2 Clinical-pathological characteristics 
The clinical features depend on the stage of the tumour. In types A and B there is no 
lymph node metastasis and it is considered to be stage I bronchoalveolar adenoma 
(bronchoalveolar carcinoma in situ) and in type C around 30% of cases show lymph 
node metastasis. The male to female ratio is 1:4 and the survival rate within 5 years is 
100% in patients with types A and B.  
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1.7.3 Smoking and lung cancer 
There are more than 4,000 toxic and carcinogenic materials in each cigarette. There are 
approximately104 free radicals in each puff, which may interrupt oxidative/anti-
oxidative balance, causing alveolar destruction. Moreover, apoptosis of the epithelial 
airways is mainly due to mitochondrial damage, and is the result of oxygen free radicals 
rather than nicotine (Wlkilson et al, 2006). 
Heat shock protein 70 is a molecular chaperone important in uniting polypeptides, 
which importantly limit cellular injury and restore the function of damaged proteins. On 
the other hand, the quantity of inflammatory cytokines is directly proportionate to the 
development of the lung cancer in which high levels of inflammatory cytokines such as 
IL6 and IL8 are correlated with the occurrence of lung cancer. Moreover, IL6 and IL8 
are over-expressed in pre-malignant epithelial cells and their expression is associated 
with a bad prognosis. Other inflammatory mediators such as C-reactive protein, a 
circulating inflammatory biomarker, are potential contributing factors to lung cancer 
 
1.7.4 Inflammation in development of lung cancer  
The role of inflammation was first described by Rudolf Virchows in 1863. He noted that 
tumours could arise from the inflammatory sites. Cancer is defined as a complex of 
disease diversity in the same cells, and usually occurs as a result of uncontrolled 
growth. Genetically normal cells are under tight control of two main classes of genes: 
oncogenes and tumour suppressor genes. The risk of malignancy increases whenever the 
activity of oncogenes exceeds that of the tumour suppressor genes. Although genetic 
inheritance remains an important risk factor, environmental and life style factors are 
considered as the main cause of genetic mutation for some diseases (Stein et al, 2004). 
Despite inflammation’s health-giving function in restoring injured tissue, it may cause 
malignancy in the surrounding areas. The inflammatory reaction and carcinogenesis 
have the same molecular aspect and signalling pathway (Yan et al, 2006). 
Chronic inflammatory response is linked to the development of cancer. It provides 
active materials from cellular inflammation of tumour areas. Examples of such active 
materials include cytokines, chemokines and growth factors, which may maintain the 
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optimum environment for the cells to avoid apoptosis and enhance other beneficial 
processes such as the reorganization of energy metabolism (Stein et al, 2004).  
Cytokines potentially are low molecular mass proteins (21 kDa) that have a role in 
cellular communication. They are synthesized by stromal cells. For example, fibroblasts 
regulate different metabolic processes, such as differentiation and migration. 
Once the inflammatory process starts, it leads to the release of these mediators that then 
play an important role in the development of tumours (Hanahan et al, 2011). Saetta et 
al, (1998) reported that IL6 is involved in the inflammatory process in human COPD, 
and has shown the highest expression in lung COPD. Moreover, high levels of 
inflammatory cytokines such as IL6 and IL8 are correlated with a high risk of lung 
cancer. IL6 and IL8 are expressed in pre-malignant epithelial cells, which expression 
implies a bad prognosis. 
 
1.8 Genetic susceptibility in COPD and lung cancer 
Genetic and environmental factors are both responsible for COPD and lung cancer. The 
risk of lung cancer in patients with chronic obstructive disease is 5 times greater than in 
healthy smokers. Genetic backgrounds are not fully understood. It is well known that 
patients with α1-antitrypsin deficiency are at risk of emphysema, as it accounts for only 
1 to 2 % of cases of COPD. Other genetic factors are mentioned in the development of 
emphysema such as TNF, which have the coding of TNF-α protein. Previous studies in 
mice show that excessive production of TNF-α protein is associated with inflammation 
and the development of emphysema (Bouma et al, 2006), and that TNF-α is involved in 
70% of COPD-related smoking. BAL (bronchoalveolar lavage) of COPD patients 
shows an increase in TNF-α compared with healthy smokers. However, the reason 
behind the increased TNF-α in COPD patients is not clear. One possibility is that the 
TNF is associated with 308A allele in different disorders. It is well known that smoking 
increases the oxidative stress and inflammatory process by inhalation of oxidants and 
invasion of inflammatory cells in the lung tissue. Moreover, both oxidative stress and 
inflammatory cascade have an effect on the cells causing genetic instability. 
Furthermore, histone tails are altered by an extensive group of non-histone chromatin 
associated proteins known as chromatin modified enzymes which are present in cells as 
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a multi-component complex that is usually recruited to chromatin with DNA bound 
transcription factors.  
Chromatin-modifying enzymes are categorized based on their function into:  
1) Acetylation by histone acetyl transferase (HATs). 2) Deacetylation by histone 
deacetylase (HDAC). 3) Methylation by methyl transferase (HMTs). 4) Demethylation 
by histone demethylases (HDMs). 
The level and activities of histone deacetylase, particularly HDAC2 and Sirtuin 
1(SIRT1), are diminished in lungs and alveolar macrophages, resulting in steroid 
resistance in COPD patients as well as reduction in HDAC2 activity, which may lead to 
acetylation of NF-KB and glucocorticoid receptor α resulting in abnormal inflammatory 
response and resistance. 
Alveolar and parenchymal macrophages show a reduction in the level of HDAC activity 
especially HDAC2 and Sirtuin. This reduction is associated with acetylation of NF-KB 
and glucocorticoid receptor-α, resulting in excessive inflammatory response in COPD. 
Since histone deacyteylases control the activity and expression of many proteins related 
to cancer initiation and progression and alteration in somatic genes encoding HDACs 
activity is related to tumour progression. It is widely believed that returning HDAC 
activity could have positive effects on steroid efficacy. For the lung cancer, the risk was 
found in carriers of mutant TP53 (Tumour protein 53). Moreover, carriers of TP53 who 
smoke have a 3 times higher chance of developing lung cancer than non-smokers 
(Hwang et al, 2003). Additionally, Hemminiki (2004) has reported germline epidermal 
growth factor receptor (EGFR) T790M sequence variation in families with NSCLC.  
 
1.8 Apoptosis in COPD and lung cancer 
Apoptosis is defined as programmed cell death, a specific program encoded in the 
genome responsible for regulated activation of cell death. Apoptosis is also considered 
as morphological aspect of cell death, which is characterized by cell shrinkage, nuclear 
condensation and membrane swelling. Apoptosis is an important aspect of homeostasis 
(the opposite of cellular division). In addition, the pathogenesis of some diseases, like 
ischemia, neurodegenerative diseases and viral diseases is related to apoptosis. 
Necrosis, on the other hand, occurs due to the effect of toxins, physical stimuli or 
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ischemia. Moreover, it can be differentiated from apoptosis by intense inflammatory 
response due to early loss of cellular content, cell swelling and nuclear lysis. 
(Vandenabeele et al, 2010). 
Nonetheless, apoptosis is involved in eliminating inflammatory cells, which is 
considered as homeostasis in the lung, this process has a harmful effect on defence 
mechanism if it exceeds normal limits. Furthermore, the abnormal apoptotic process is 
related to the development of emphysema (figure 1.16), fibrosis, and bronchiolitis 
obliterans (non-reversible collapse of small airway) (Kasahara et al, 2001). The process 
of apoptosis is usually not easily detectable in pneumonia, however in severe 
inflammatory diseases, such as fibrosis, it could be obvious due to inefficient clearance 
(Vandivier and Gardai, 2005).  
Phagocytosis in COPD is involved in the process of the elimination of apoptotic cells, 
fibroblasts, epithelial and endothelial cells. Moreover, macrophages and dendritic cells 
are responsible for this process. Previous studies in COPD patients showed that the 
inefficient removal of dead cells may be responsible for the disruption of alveolar 
structure (deCathelineau et al, 2003). Furthermore, engulfing and necrosis of dead cells 
could lead to the release of some inflammatory mediators, which may initiate the 
immunological response and attract more inflammatory cells in the surrounding tissue. 
Hence, the elimination of the apoptotic cells is a crucial step to restore normal tissue 
function. 
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Figure 1.18| Involvement of inflammatory mediators in apoptosis. Ineffective 
efferocytosis (effective removal of dead cells by phagocytic cells) result in endothelial 
cells regression and matrix turnover. (B) Normal removal of dead cells maintains 
balance and prevents excessive release of inflammatory mediators that may cause 
erosion of the endothelium (Edward et al, 2009). 
 
Programmed cell death is the principle of tumour prevention and usually occurs in 
normal cells as a protective mechanism. In addition, oncogenes that become active in a 
tumour inhibit the apoptosis of abnormal cells (Green and Evan 2002; Lowe et al, 
2004).  
The elimination of unwanted cells is regulated by apoptosis, which is a highly organized 
process of programmed cell death (Figure 1.16). Two different pathways, depending on 
the source of death stimuli, have been described in the cell cycle, intrinsic and extrinsic 
pathways (Figure 1.19), which they categorized according to the source of stimuli. The 
first pathway (intrinsic pathway) is stimulated by internal stress signals such as DNA 
damage, starvation and the oxidative stress (Scmitt and Lowe, 1999; Mayer and 
obubauer, 2003). In turn, the mitochondrial proteins leak to trigger apoptosis 
(Hengarner et al, 2000; Saelens et al, 2004). Upon release of mitochondrial proteins, 
cytochrome C initiates a dismantling of cellular components, leading to cell death 
(Degeterve et al, 2003). The second pathway (extrinsic pathway), in which the external 
sources such as cytokines activate the extrinsic pathway by the binding of the death 
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ligand of TNF superfamily and TNF-related apoptosis to cell surface death receptors 
(TNF receptor 1 and 2) (Walczac and Krammer, 2002; Lavrik et al, 2005).This in turn, 
activate the pro-caspase-8 after formation of death inducing signalling complex (DISC), 
leading to induction of mitochondrial permeability or triggering a protease cascade, 
which ends by death (Scaffidi et al, 1998; Fluda et al, 2002). 
Figure 1-19| Different pathways of apoptosis in COPD and pulmonary emphysema, 
Intrinsic and extrinsic stimuli initiated by internal and external stimuli, which mediates 
two different pathways (Demedts et al. 2006).  
 
Several studies carried out in COPD lung were focussing on apoptosis. Imai and 
colleagues (2005) pointed to decrease in the apoptosis in lining epithelial surface and 
endothelium in COPD patients and concluded the reduction in level of apoptosis of 
inflammatory cells could be responsible for chronic inflammatory process. 
 
1.9.1 Effect of glucocorticoids on apoptosis 
Glucocorticoids are used mainly as anti-inflammatories and immunosuppressant, 
however they are also able to induce apoptosis in many cell types and tissues (Chrouses 
et al, 2007). In glucocorticoid-sensitive cells, the GR mediates glucocorticoid apoptotic 
effect. The classical signalling and modulation is mediated by the high expression of 
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GR-α, while the role of GR-β is not well-defined and may be inversely correlated with 
the inhibition of GR-α.  
Various isoforms of GR-α translation are related to different apoptotic rates. Apoptosis 
is induced by a group of proteins known as caspases. The caspase proteins are activated 
through the mitochondrial pathway. One of the immunomodulatory activities of 
glucocorticoids is to induce T-cell apoptosis. There is evidence that in the majority of 
white blood cells glucocorticoids use the intrinsic pathway to induce apoptosis by 
affecting pro-apoptotic members of the Bcl-2 family (like Bim) or blocking the anti-
apoptotic members (Han et al. 2001, Wang et al. 2003, Lu et al. 2007). Moreover, in 
one study of glucocorticoid-induced apoptosis, the authors showed that there was a 
difference between cell lines, with the mitochondrial pathway being activated by 
glucocorticoids only in certain types of cell. (Sionovet al. 2006). 
The purpose of steroids in the management of lung cancer is to enhance cell death or 
apoptosis, however treatment commonly fails. In addition, glucocorticoids are used as 
adjuvant therapy in the treatment of solid tumours to reduce oedema, pain and 
electrolyte disturbance. They are also used in conjunction with chemotherapy because 
of their pro-apoptotic properties in lymphoid cells and because they can reduce the toxic 
effect of chemotherapy in healthy tissue (Rutz, 2002, Rutz; Herr 2004). 
 
 
Figure-1.18|. Mechanism of glucocorticoid mediated apoptosis. Genomic and non-
genomic pathway of glucocorticoid mediated apoptosis, leading to activation of caspase 
via mitochondrial pathway. (Elmore et al, 2007) 
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Aim and hypothesis 
The risk of lung cancer among COPD patients is higher than in heathy individuals. 
Moreover, the degree of structural change and the variety of cells recruited in COPD 
patients is different from those in the case of other inflammatory diseases like asthma. 
Treatment failure is common in COPD, and glucocorticoid resistance in COPD and lung 
cancer is considered the main issue. Our study highlights the effect of glucocorticoid 
hormones on the transcriptional activity of glucocorticoid receptors. We hypothesize 
that the stress cofactor TTC5 is important for the stability and the post-translational 
modification of glucocorticoid receptors. In this thesis, we examine the importance of 
glucocorticoid receptor phosphorylation on the transcriptional activity of glucocorticoid 
receptors, in lung cancer cell line (A549), as well as lung tissues of healthy and COPD 
patients, also, we hypothesize that TTC5 interacts with phosphorylated glucocorticoid 
receptors at multiple sites including S211, S226, and affects the activity of 
glucocorticoid receptors  
There is evidence suggesting that inflammatory mediators such are IL6 have an 
orchestrating role in the pathogenesis and the course of chronic obstructive pulmonary 
disease. One cross-sectional study showed that increased IL-6 in the sputum of COPD 
patients is directly proportionate to the disease severity. Based on these findings, our 
study will examine the expression of IL-6 in the peripheral lung tissue of COPD 
obtained from different groups of patients compared to healthy individuals. Moreover, 
on tissue level, we will examine the expression of glucocorticoid receptors and of the 
novel stress cofactor TTC5 in the macrophages and the epithelial surface, and in 
particular, how this expression varies with smoking status and the rate of decline in the 
pulmonary function. These findings could contribute to development of novel 
biomarkers of disease progression and drug sensitivity and improve therapy. 
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Chapter 2 Material and methodology 
 
2.1.1 Methodology 
Three procedures were used in this research namely maintaining the cell lines and 
western blot technique, co- immunoprecipitation and immunohistochemistry.  
 
2.1.2 Maintaining the cells 
Human alveolar adenocarcinoma cell line (A549 cells) were maintained in a Roswell 
Park Memorial Institute (RPMI) culture media. . Sterile media was with sodium 
bicarbonate and without L-glutamate which acts as intermediary between ammonia and 
ammonic acid and as nitrogen source in vivo. About 90ml of media with 1% penicillin 
was supplemented with 10ml foetal bovine serum (FBS) and 1ml glutamate. A549 cells 
were inspected on regular basis under a light microscope for possible bacterial or fungal 
infection and contamination. 
 
2.1.3 Feeding of the cells 
Feeding of cells with nutrients and amino acids was required to maintain healthy cells. 
The media was replenished every 2 to 3 days, the media was prepared under as a septic 
technique. For safety and infection control purpose, the pipettes were changed in every 
step in order to avoid microbial contamination.   The cells washed two times with warm 
sterile PBS and the existing media replaced by new one then the cells incubated in 37C 
(5% CO2).    
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2.1.4 Splitting of the cells 
The aim of splitting of the cells was to maintain the cells' growth in optimum condition 
with enough nutrient supply. The splitting was performed whenever the confluence of 
the cells was 70% or more. Safety and infection control measures was followed before 
the procedure. The trypsin and PBS were wormed to match body temperature for 
enzymes activity at 370C, then the cells washed twice with warm PBS. In the following 
step about 1ml of Trypsin was added to the cells and left for about 3 minutes in 370C. 
The flasks were tapped from the sides to detach the cells from the flask and then 
observed under the microscope to ensure complete detachment. Once the cells were 
detached, they were counted using haemocytometer under the microscope. The trypsin 
was deactivated by adding 10 ml of new media. The following step was dividing the 
amount of the media between two or more flasks depending on confluence and then 
filled up to 10 ml of media was added to each flask.  
 
2.1.5 Counting of cells 
The cells were counted using a sterile haemocytometer. About 25µl of well mixed cells 
were added to 100µl of trypan blue dye and then loaded on the sides and observed under 
light microscope using 10x power. The vital cells which were located at four side 
chambers of the haemocytometer were counted and the dead cells which were blue were 
not counted. The total amount of cells in the four chambers are divided by four.  
.                                                                                                        
Figure 2.1 haemocytometer under the microscope. 
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2.1.6 Freezing of the cells 
In order to freeze cells, cells were washed twice with sterile PBS followed by detaching 
the cells with 1ml trypsin and incubation in 370C for three minutes. The following step 
was adding 10 ml of media, centrifuge cells for 2 minutes at speed of 2000 rpm and 
wash them with PBS. The final step in the freezing was adding 1800 µl FBS and 200µl 
DMSO- (Dimethyl sulfoxide).The samples left in -20 for 24 hours before transferring 
into the -80 degree. 
 
2.1.7 Cell treatments  
The drug of choice was dexamethasone (1µM per 10 ml culture media for 16 to 18 
hours). Dexamethasone is manufactured steroid which possesses anti-inflammatory and 
immuno-suppressant effect, the potency of dexamethasone is 25 times stronger than 
glucocorticoid, however it is weak mineral-corticoid hormone. 
It is widely prescribed in management of allergic and immunological conditions such as 
asthma, chronic obstructive pulmonary disease, fibrosis, rheumatic diseases etc.  
Before the treatment with dexamethasone, the media was supplemented with 1 ml 
glutamate and 10% DDC/FCS instead of FCS. 
                                                                    
Figure 2.2| chemical structure of dexamethazone. Adopted from 
http/pubchem.ncbi.nlm.nih.gov/compound/5743 
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2.1.8 Protein extraction 
Glucocorticoid receptor is a cytoplasmic protein and the aim of extraction was to 
analyse the protein condition and the affinity to dexamethasone hormone (treated cells 
with dexamethasone) relatively to control cells. The extraction of the protein was 
carried out using 120 µl high salt lysis buffer containing protease inhibitors per well that 
were previously washed with cold BPS three times. Protein extraction was done on ice 
to keep the proteins stable and the extracted protein was collected in Eppendorf tubes. 
Then the samples were rotated for 20 minutes followed by centrifuged for another 20 
minutes at 12 rpm in 4C.  
The samples collected and the pellets discarded. The protein concentration was 
measured by Spectrophotometer (protein absorbance measured at 595 nm. Jenway, 
Genova) aimed to have the same quantity of protein in both treated samples and the 
control samples. Acquiring the same amount of protein was essential to avoid false-
positive or false-negative results. Moreover, the protein concentration was measured 
twice in order to acquire an average reading. Each sample was a mixture of 200µl of 
Bio-Rad reagent plus 800µl of distilled water and about 2µl of the extract were added to 
each sample before measuring the amount of protein (one sample was used as blank 
without any extract). After the measurement a simple calculation were used for 
quantification of protein of both control and treated cells, and then protein kept in -200 C 
with 3x DSD buffer before analysed by Western blot technique.  
 
2.1.9 SDS- PAGE  
SDS- PAGE is the way to determine protein amount and molecular weight. It is 
followed by the western blot analysis that uses antibodies to detect specific protein. 
Western blot technique is based on detection of molecular proteins on nitrocellulose 
membrane, thus enabling to identify specific proteins from target cells, this technique 
depend mainly on separation according to size of protein, and identifying target protein 
by using specific primary and secondary antibody. 
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2.1.10 Running 
 Before running the samples with 1x DSD buffer (made from 10x buffer that has made 
by dissolving 30.2g Tris base and 144g glycine), the sample was boiled at 950 C for 5 
minutes and then the samples are subjected to 7.5 acryl amid gel (formula below), the 
samples run on 80 milliamp for stacking gel and 110 milliamp until the end of the 
resolving gel. 
Acryl amide gel 7.5%  
The resolving gel was prepared according to this formulation 
Distilled water ..........13.3 ml                                                                                                            
Acryl amide 30% ........7 ml                                                                                                       
1.5M Tris (Ph8.95).....7ml                                                                                                       
0.2M EDTA ..............280µl                                                                                                    
10% SDS...................280µL                                                                                                   
10% APS..................157µl                                                                                                          
TEMD.......................17µl 
The stacking gel was prepared according to this calculation                               
 
Distilled water .................6.73ml                                                                                          
Acryl-amide 30%.......1.67ml                                                                                              
1M Tris (Ph6.95).............1.25 ml                                                                                           
0.2M EDTA.......................100µl                                                                                            
10% SDS..............................100µL                                                                                      
10%APS...............................157µl                                                                                          
TEMED.................................17µL 
 
2.1.11 Transfer 
Once running the samples finished, the polypeptide bands are transferred into the 
nitrocellulose membrane using 1x western transfer buffer, that was prepared by adding 
100 ml of 10x western transfer stock to 200ml methanol and 700 ml dH2O, transfer was 
carried out for 2 hours, this step was crucial as the protein transferred from the gel into 
the membrane. Firstly the filter paper was soaked into a transfer buffer, while the 
transfer membrane submerged in methanol for 30 sec and then washed with the transfer 
buffer.  A holder was prepared by assembling the following a sponge, filter paper, 
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transfer membrane, gel, a filter paper and a sponge from the outside, (bubbles were 
removed by rolling pin). The protein was transferred at 40 C by using ice and magnetic 
starrier that was placed inside. 
 
2.1.12 Blocking 
The aim of blocking was to avoid any non-specific interaction between the antibody and 
non-specific proteins. This step was carried out by incubating a Imobilon P membrane 
in blocking mixture (5% of skimmed powder milk in PBS buffer) for one hour at room 
temperature on a shaker.  
 
2.1.13 Incubation with primary antibody 
The membrane was incubated in each experiment with specific primary antibody to the 
protein of interest overnight at 40 C on a rotator (about 3 µl of primary antibody were 
added to milk/PBS/ 0.1 % tween. 
 
2.1.14 Incubation with secondary antibody  
Prior to the development which was on the second day, the membrane was washed three 
times with PBS tween for 10 minutes interval, and then incubated with the secondary 
antibody for one hour at room temperature (from 2-4 µl of secondary antibody was 
added to 10 ml of milk/PBS/tween 
 
2.1.15 Development  
This was the last step in western blot technique. It was done by incubating the 
membrane from 1-2 minutes in enhancer ECL mix (about 1000µl from each bottle of 
western pico), then developed by X-ray machine.  
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2.1.16 Stripping  
It was useful to strip the membrane in order to reuse it with another antibody. The 
stripping was applied to the nitrocellulose membrane considering the following three 
steps. First step was to prepare the chemicals by adding exactly 10ml of 10% SDS to 
3.2 ml of Tris (PH8.5) in a universal tube, and the completed with distilled water up to 
50 ml of the universal tube. Finally under the chemical hood 350µl of 2-
mercaptoethanol was added to the total amount. The second step was to place the 
membrane into autoclave where heated up to 50 degree for exactly 30 minutes, agitation 
applied sometimes aimed to remove any chemicals from the membrane. The last step 
was washing the membrane on a shaker twice with PBS tween for about 10 minutes, 
and then blocked with 5% of skimmed powder milk in 1 times TBS buffer before 
incubation with another antibody. 
 
2.2 Co-immune-precipitation 
It is a common purification technique usually to detect any possible interaction between 
two molecules of proteins, by using specific antibody to the protein of interest (target 
protein). The aim of the Co-immuno-precipitation in this research was to detect any 
possible interaction between different forms GR (H-300, phosphorylated S211 and 
S226) and TTC5 in physiological condition in vitro. The TTC5 was the protein of 
interest which added to cell lysate and identified each time by different antibody of GR.  
 
. 
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Figure 2.3| Co-immunopricipitation process using protein A sepherose. 
(http://www.assay-protocol.com/Immunology/Co-IP). 
 
Co immunoprecitation was carried out as the following:  
 
2.2.1 Cell maintenance  
Obviously maintaining the cells and the splitting was the same as usual .However the 
buffer used for the protein extraction was 250µl of TNN buffer (50mM Tris PH7.5, 
120mM Na Cl, 5mM EDTA, 0.5% Igepal, 1µg/ml PI, 1mM DTT, 1mM PMSF, Sodium 
orthovanadate , 5mM Sodium pyrophosphate, 20 mM β- glycerophosphate ) per well 
plate instead of high lysis buffer . 
About 20 µl of protein A sepherose beads (magnetic beads, Sigma) washed three times 
with 200µl of the same puffer used for cell lysate which is TNN buffer.  
Some samples were saved as input in -20 and the remaining of the samples incubated 
with the primary antibody for the protein of interest (TTC5) overnight at 4C. In the 
second day the samples centrifuged at 12000 rmp, for 3 minutes and the pellet washed 
three times with TNN buffer at the same rate. The last step were adding 30 µl of SDS 
.before analysed with indicating antibody by western blot the samples boiled at 90 C for 
5 minutes. 
Cell 
lysat
e 
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2.2.2 Immunohistochemistry  
In this procedure, the monoclonal and polyclonal antibodies was used to observe in situ 
detection of antigens in lung tissues. The aim was to detect expression of glucocorticoid 
receptors and protein distribution in the lung tissues in different stages of COPD 
compared to clinical data for each group. Samples was obtained by bronchoscopy and 
lobectomy from COPD patients (permission and written consent has been taken from 
the patients). 39 patients were involved in this study and have been categorized 
according to NHS classification into 5 groups. Healthy ex-smokers, mild COPD, 
moderate COPD, Sever COPD and COPD with lung cancer. 
The samples underwent many steps before the investigation. The first step was 
embedding and cutting in which, the tissue cut into small pieces and kept in cuvettes at 
room temperature. The cuvettes first stored overnight in 10% formalin and then 
processed through several different concentration of ethyl alcohol, 70% ethanol for 1 
hour, 90% ethanol for 40 minutes and 100% ethanol for 40 minutes for 4 times, then 
transferred into Xylene1 and Xylene2 for 30 minutes respectively. The last step in the 
processing was transferring the tissue into a new cuvette were the wax added and the 
left over night in cool place.  
 
2.2.3 Patient’s demographics 
39 patients from Wythenshawe hospital were investigated and analysed compared with 
clinical values (smoking status, FEV1, FEV1/FVC ratio) after written consent using 
immune-histochemistry technique. The lung biopsies in this research obtained from 
different regions in the lung with safety distance from the tumours, and processed into 
different concentration of ethyl alcohol, then cut by microtome into slides of 5µm in 
diameter The pathophysiological changes were similar in each group and airway 
obstruction was assessed by measuring FEV1/FVC ratio and predicted FEV1 (The 
standard deviation showed no significant difference in each group.  All the clinical data 
and pathological characteristics are summarized in the table below. 
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 Healthy 
non-
smokers 
Heathy ex-
smokers 
Healthy 
smokers 
COPD ex-
smokers 
COPD current 
smokers 
Number of     
patients 
        
3 
       
10 
    9 9 8 
Age 
 
73.3 (SD 
6.8) 
70.3 (SD 
12.2) 
59.5 (SD 
10.3) 
68.3 (SD 8.1) 68.25 (SD 5.7) 
Gender 
 
2Female,  
1Male 
    
FEV1 
 
2.2 (SD 
0.39) 
2.19 (SD 
0.45) 
2  (SD 0.7) 1.38 (SD 0.36) 1.76 (SD 0.4) 
FEV1 
predicted 
101.6 
(SD2.35) 
96.3 (SD 
22.1) 
86.5 (SD 
19.3) 
60.7 (SD 6.5) 72.7 (SD 
10.48) 
FVC 
 
2.81 (SD 
0.36) 
2.8 (SD 
0.67) 
3 (SD 
0.81) 
3.5 (SD 1.04) 3.1 (SD 0.7) 
FEV1/FVC 
ratio 
78.72 
(SD 3.8) 
77 (SD 7.1) 68.7 (SD 
9.3) 
51 (SD 9.8) 57 (SD 8.4) 
Height 
 
162 cm     
Smoking 
history 
Never EX-smokers 
Past history 
35.3pack/ye
ar SD (15.5) 
Current 
smoker(42.
4 P/year) 
SD (17.1)  
Ex-smokers 
with COPD 
Stage II (33.9 
Pack/ year) SD 
(21.7) 
Current 
smokes with 
different stages 
of 6 patients 
with stage II, 
and two 
patients in 
stage I and III. 
Medication 
 
Non Non Non Bronchodilator
s+ Long acting 
beta-agonists in 
combination 
with steroid 
Bronchodilator
s, long beta 
agonists in 
combination 
with steroid 
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(Seretid discus) 
and/or 
anticholinergic 
(Spiriva). 
(Seretid discus) 
and/or anti 
cholinergic 
drugs (Spiriva)  
Pathologica
l findings 
Normal 
architect-
ure of 
lung 
tissue 
without 
obvious 
alveolar 
destructio
n seen 
Variable 
number of 
macrophage
s with non-
distinguish 
border and 
angiogenesi
s in the 
majority of 
the patients, 
however no 
evidence of 
alveolar 
destruction 
 
Few to 
Moderate 
number of 
macrophag
aes with no 
alveolar 
destruction 
 
Moderate to 
large number 
of macrophages 
associated with 
alveolar 
destruction in 
some patients 
moreover tar 
deposition.  
Mild to 
moderate 
number of 
macrophages 
associated with 
alveolar 
destruction and 
some epithelial 
disruption. 
Table 2.1 illustrates patient’s demographics and histopathological changes in each 
group of patients (complete patient’s demographic supplemented in table 4.1) 
 
2.2.4 Optimization  
The aim of optimization was to confirm specificity to antibodies and to achieve the best 
dilution for the antibodies relevant to pre-treatment condition. And it was important to 
test serial sections with different buffers to the same antibody. 
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 Antibody 
dilution for 
IHC 
 
 
Antibody 
species (and 
associated 
vector kit) 
Pre-
treatment 
needed (y/n) 
Pre-
treatment 
buffer 
Company order 
code + clone 
   IL-6 1:100 
 
 
 
mouse         n CB abcam 
AB9324 500µg 
providedand 
diluted in 500µg 
to yield 1mg/1ml 
Total GR H-
300 
   1:1000 Rabbit- 
polyclonal 
        n n/a SantaCruz sc-
8992 Provided at 
200ug/ml  
  S226 
GRphospho 
226 
1:100 
 
 
 
Rabbit 
polyclonal 
y TEB Abcam:ab536925
µg/ml, heat 
antigen retrival 
CB PH6 
Recommended by  
Abcam 
   S211 
GRphosphop
horylated at 
211 
 
1:1000 
 
 
 
Rabbit 
polyclonal 
y EB Cell Signaling 
#4161100ul 
provided but no 
info on 
concentration 
TTC5 1:500 Rabbit 
polyclonal  
      n 
 
n/a Abcamab36855U
se at 10ug/ml 
Table 2.2 serial dilution for different antibodies (TGR, S211, S226, TTC6 and IL-6) 
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2.2.5 Immunohistochemistry technique 
The first step in the procedure was dewax by the tissue by histoclear reagent (National 
diagnostic) I and II for 5 minutes, aimed to deparaffinise the slides. Then the slides 
transferred into different concentration of alcohol100% for 5 minutes, 90% for 3 
minutes, 75% for 2 minutes, 75% for 2 minutes and 50% for 1 minutes then the slides 
placed into a running water for 5 minutes before pre-treatment with different buffers 
before the pre-treatment  with different buffers according to the optimization carried out 
before the incubation with the primary antibodies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
The aim pre-treatment was aimed for expose epitopes retrieval( the binding part of the 
receptors) , which may be masked by formalin during fixation procedure  . Heat applied 
with different solutions for epitope retrieval. Citrate buffer prepared by dissolving 2.1g 
of citrate in 1000ml distilled water (PH 6 with 1M HCL). 1mM EDTA buffer prepared 
by dissolving 0.37 g of EDTA in 1000 distilled water and PH to 8. And Tris-EDTA 
buffer prepared by adding 1.21g Tris base and 0.37g EDTA to 1000ml distilled water 
(PH to 9 where 0.5 ml tween 20 was added).                                                                                                                                 
Blocking serum was important step in order to prevent non-specific hydrophilic binding 
between non-specific protein and primary antibody other than those attractive to 
receptors. Blocking the normal serum carried out by incubation of 100 µl (15µl of 
normal serum in 1000 µl TBS. 
The last step in the first part of the immunohistochemistry was incubating the samples 
in the primary antibody for about 2 hours up to 18 hours the primary antibody was 
added to the normal blocking serum and 100µl was applied. 
In the second part and before the incubation with secondary antibody, the samples 
washed three times with PBS tween, then the samples incubated in Vector biotinylated 
secondary antibody  which was prepared by adding 15µl of normal blocking serum and 
5µl of secondary anti (mouse/rabbit) IGg to 1ml TBS. The incubation with the 
secondary antibody was 1 hour, and then washed again with TBS three times. 
After the incubation with the secondary antibody and to avoid inconvenient staining it 
was necessary to block endogenous peroxidase by incubating the samples in 3% H2O2 
with methanol for half an hour, (the mixture was prepared by adding 48.5 ml of 
methanol to 1.5 hydrogen peroxide3%).  
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Before washing with TBS and running water for 5 minutes the ABC (Avidin-
biotinylated complex) prepared and left for 30 minutes in room temperature. Any 
biotinylated molecule can be detected by ABC because of high affinity property of 
avidin to biotin. 
 
 
Figure2.4| using ABC system. (https://www.vectorlabs.com/uk/catalog.aspx?catID=42) 
 
The samples washed three times by PBS tween, then incubated with DAB substrate (3, 
3’ diaminobenzidine), dark brown reaction was the end result under the microscope and 
this reaction stopped by distilled water. And the haematoxylin stain was applied from 
20 to 40 seconds and rainsaned with excess of water (Haematoxylin is diagnostic dye in 
histology field and counter stain to nuclei in immunohistochemistry. the nuclei are 
stained blue as oxidized haematoxylin bound to aluminium ions. And before the last 
step of dehydration, the slides put under running water. The dehydration was by 
different concentration of ethyl alcohol as following. 50% ethyl alcohol for 1minute,  
75% ethyl-alcohol for 2 minutes,                                                                                                                                                                                                
75% ethyl-alcohol for 2 minutes,   90% ethyl-alcohol for 3 minutes, 100% ethyl-alcohol 
for 5 minutes lastly clearance was through xylene II and xylene I for 5 minutes each 
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respectively                                                                                                                                                                           
then the slides covered with slip s were DPX had applied  
 
2.2.6 Image-J  
Image-j is analytical program, its idea adopted from NIH image which was developed 
first time by research service branch (RSB) of the natural institute of mental health. It 
can be downloaded for free from http://rsbweb.nih.gov/ij/download.html. 
Multiple tasks can be performed by image j including quantification of protein amount 
in western blot, also it is important tool in the pathology field which can be used in 
counting the number of cells like Macrophages, measurement of surface area in tissues 
and density histogram, the steps of cell counting are explained in the following diagram 
 Figure 2.5 Plugins-Analyse-Cell counting process by image-j. A shows multiple 
windows available on the front, starting by file image option, and plugins window 
which is characterized by analysing the slides through cell counting icon. In picture B 
illustrates analysis process which involving many characters like counting each type 
separately and total calculation at the end of counting.   
 
 
2.3 Material  
Different materials were used in processing the lung tissues and different antibodies as 
well as chemical reagents used for western blot and Co-immune-precipitation. All the 
materials are mentioned in the table below as well as the supplier and the product code. 
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2.3.1 Substances 
Different chemicals were used in this research including buffers, steroid drugs and 
different antibodies 
 
2.3.2 List of chemical reagents 
 
 
   Name of the chemical 
 
Supplier 
 
 
 
 Product code 
        Dexamethazone Sigma  81K1100 
           Penicillin Labtech  LM-A4118/100 
            Formalin    
        Hydrogen peroxide    
          Histoclear I                              
          (d-limonene) 
National diagnostic   
          Histoclear II National diagnostic   
               DPX    
             Citrate     
             EDTA Sigma-
Aldrich, UK  
 E6760 
          Tris EDTA    
        Ethyl alcohol Fisher, UK  E/0600/05 
FCS/FBS(Dextran coated 
charcoal treated FBS) 
Supplier, UK   
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            Vericol Fisher, UK  005414182 
     Trypsin (500ml) Labtech  LM-
T1705/500 
(Dimethylsulfoxide) hyprid-
max-sterile filtered (DMSO) 
(SLS) 
Scientific 
Laboratory 
Supplies, UK 
 D2650-
5X5ML 
        Biorad protein essay Bio-Rad  500-0006 
    
                 SDS Fisher UK  S/P530/48 
      High Lysis Buffer 1   
             TTN buffer 2   
    30% Acryl National diagnostic  Ec-890 
     0.2M EDTA    
Page Ruler Prestained protein 
ladder 
Fermentas, UK  SM0672 
               TEMD (N.N.N.N) 
Tetramethylethylenedaimine 
Sigma  BCBH1254V 
            Tris base Fisher, UK  BP152-1 
 PMSF (Phenylmethanesulfonyl 
Fluoride) 
Sigma  044K0157 
   BGP (Disodium Pentahydrate)    
             DTT Sigma UK  D0632 
           Na OV Sigma UK  S6508 
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APS 10% (Ammonium per 
sulphate) 
Flowgen, UK  H17423 
          Glycine Fisher  1211411 
Sodium dodecyl Sulphate Fisher  114840 
           Na PPI    
        TBS buffer Fisher           10214733  
(PBS) Phosphate buffer 
saline 10X 
Fisher, UK   
           Tween 20 Sigma  029Ko1855 
 Western Pico enhancer Thermo  N178744 
        Western Femto super-signal Thermo  NH173984 
 2-Mercaptoethanol Sigma-
Aldrich, UK 
 M3148 
Sodium pyrophosphate    
            Methanol Fisher UK  BPE1105-1 
         Haematoxylin     
           ABC reagent Vectastain  PK-6100 
            DAB substrate   PK-6100 
          Goat serum            Vectastain   
      Total GR      (H300) Santa Cruz 
Biotechnology 
 SC-8992 
      Phospho GR  ( S211) Cell Signaling  4161 
      Phospho GR  (S226) Abcam  Ab 53692 
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 TTC5 (Tetratricopeptide                  
repeat domain 5)  
 
Abcam  Ab36855 
          Interleukin 6 abcam  Ab 9324 
          Β-actin  abcam  ab8227 
          Glycerol Fisher chemical  1291109 
Secondary anti-mouse GE-Healthcare  5356526 
Secondary anti-rabbit IgG GE-Healthcare  5272514 
          Actin Abcam  Ab8227 
          X-ray Fuji film UK  Super Rx 
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III. Results 
3.1 Determination of GR and TTC5 protein levels in lung cancer cell line 
The main purpose of western blot in adenocarcinoma cell line (A549 cells), was to 
investigate the difference in protein expression after treatment with long acting 
corticosteroid (Dexamethasone). Three main forms of glucocorticoid protein (total GR, 
S211, S226) were investigated in addition to TTC5 (tetratricopeptide repeat domain 5) 
and Interleukin-6. The procedure was performed by making a protein extract from 
control and hormone treated cells, and by loading the whole cell lysate on 7.5% 
polycrylamide gel. Actin protein was used as a loading control. The quantity of target 
protein was measured by image-J comparative to the control (Figure 3.1).  
 
 
 
 
 
 
 
                                                                                          
Figure 3.1| Measurement of protein expression (total GR) in A549 cells. (A) The level 
of expression in total GR relative to actin gene in A549 cells treated with 1µM 
dexamethasone. The whole cell lysate was analysed by SDS-PAGE using 7.5% gel, this 
was followed by western blot transfer and antibody analysis with total GR and actin. (B) 
Protein expression of TGR. The percentage of expression was obtained by 
normalization of non-affected gene (Actin). The results represents the averages of five 
different experiments (supportive figures 5.1), and the error bars represent SD (13.71) 
(figure 3.1 B). P value < 0.01 (shown in supplementary figure, table 5.2). 
In this series of experiments the protein level of total GR was measured in A549 lung 
cancer cell line (Figure 3.1 and supplementary figure 5.1 in the appendix).).  Protein 
expression of TGR shown in lane 2 compared to lane 1, was down-regulated by 53% in 
A549 cells treated with dexamethasone as compared to un-treated cells (figure 3.1 A 
and B, compare lane 2 and lane 1). Results show that GR is down-regulated (figure 3.1 
A, lane 2) in A459 cells treated with dexamethasone. 
 
 
 
B 
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Figure3.2| Measurement of protein expression (S211) in A549 cells. (A) The level of 
expression in phosphorylated GR at S211 in treated A549 cells with 1µmol 
dexamethasone. The whole cell lysate was analysed by SDS Page using 7.5% gel, this 
was followed by western blot transfer and antibody analyst with S211 and actin. (B) 
Relative protein expression of S211. The percentage of expression was obtained by 
normalization of non-affected gene (actin). The result represent the averages of three 
different experiments (supportive figures 4.2), and the error bars represent SD (28.28), 
(figure 3.2 B). P value< 0.01 (shown in supplementary figure, table 5.2).  
In order to analyse GR phosphorylation status in lung cancer, GR phosphorylated on 
serine 211 was followed by SDS PAGE (Figure 3.2 and supplementary figure 5.1 in 
appendix). Protein expression of S211 shown in lane 2 compared to lane 1, was 
massively up-regulated in A549 cells treated with dexamethasone as compared to un-
treated cells (figure 3.2 A and B, compare lane 2 and lane 1). Results show that S211 is 
up-regulated (figure 3.2 A, lane 2) in A549 cells treated with dexamethasone. 
 
 
 
B 
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Figure3.3 Measurnement of protein expression (S226) in A549 cells. (A) The level of 
expression in phosphorylated GR (226) related to actin gene in A549 cells treated by 
dexamethasone. The whole cell lysate was analysed by SDS Page using 7.5% gel, this 
was followed by western transfer and antibody analysis with S226 and Actin. (B) 
Quantification of protein expression. The percentage of expression was obtained by 
normalization of non-affected gene (actin). The results represents the averages of five 
different experiments (supportive figures 4.2), and the error bars represent SD (5.85) 
(figure 3.3 B). P value < 0.05 (shown in supplementary figure, table 5.2).  
In this series of experiments the protein level of S226 was measured in A549 lung 
cancer cell line (figure 3.3 and supplementary figure 5.1 in the appendix). Protein 
xpression of S226 shown in lane 2 compared to lane 1, was up-regulated by 11% (figure 
3.3A, lane 2) in A549 cells treated with dexmethasone. 
                                         
   
Figure 3.4| Measurement of protein expression (TTC5) in A549 cells. (A) The level of 
expression in TTC5 (Strap) related to actin in A549 cells treated with 1µM 
dexamethasone. The whole cell lysate was analysed by SDS Page using 7.5% gel 
followed by western blot transfer and antibody analysis with TTC5 and actin. (B) 
Quantification of protein expression using image J. The percentage of expression was 
obtained by normalization of non-affected gene (actin). The results represent the 
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averages of three independent experiments (supportive figures 5.1), and the error bars 
represent SD (62.93) (figure 4.1 B). P value < 0.05 (shown in supplementary figure, 
table 5.2).  
The protein level of TTC5 was measured in A549 lung cancer cell line (Figure 3.4 and 
supplementary figure 5.1 in the appendix). Protein expression of TTC5 shown in lane 2 
compared to lane 1, was up-regulated by 80% in A549 cells treated with dexamethasone 
as compared to un-treated cells (figure 3.4 A, lane 2) in A549 cells treated with 
dexamethasone.  
 
 
 
Figure 3.5| Measurement of protein expression (IL6) in A549 cells. (A) The level of 
expression in IL6 related to actin gene in A549 cells treated with 1µM dexamethasone. 
The whole cell lysate was analysed by SDS Page using 12% gel, followed by western 
transfer and antibody analyst with IL-6 and actin. (B) Protein expression of IL-6 in lane 
2 compared to lane 1(figure 5A and B, compare lane 2 lane 1). The percentage of 
expression was obtained by normalization of non-affected gene (actin). The percentage 
of expression represent only one reading. 
In this experiment the protein level of IL6 was measured in A549 lung cancer cell line 
(figure 3.5A). Protein expression of IL6 shown in lane 2 compared to lane 1, was down-
regulated by 52% in A549 cells treated with dexamethasone as compared to un-treated 
cells (figure 3.5A, lane 2) in A549 cells treated with dexamethasone.  
 
3.2 Conclusion of western blot experiments 
In summary, in lung cancer cells treated with synthetic glucocorticoid dexamethasone, 
protein levels showed down regulation of total GR, slight increase in expression of the 
GR phosphorylated on S226, and substantial up-regulation of the GR phosphorylated on 
S211. On the other hand the expression of TTC5 was variable in three different 
 
 
 
 
 
 
A B 
B 
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experiments. Preliminary results suggest that dexamethasone causes marked down 
regulation of IL6. 
         
 
3.3 Analysis of protein-protein interaction using Co-immune precipitation  
Glucocorticoid receptors mediate varied physiological processes. They interact with a 
number of proteins which are considered as co-regulators because they control gene 
transcription by repression or activation. TTC5 has been identified as co-regulator of 
p53 tumour suppressor that controls cell cycle progression and stress response 
(Demonacos et al, 2001). In this experiment we analysed possible interaction between 
glucocorticoid receptors and TTC5. 
The aim of co-immunoprecipitation was to detect interaction between total 
glucocorticoid receptor protein, phosphorylated glucocorticoid receptor at S211 Serine 
226 and TTC5. The procedure was carried out by incubation of the cell lysate with 
protein A-sepharose and antibody against the protein of interest (TTC5) were affixed to 
the complex and left in a rotator overnight at 40C. About 5% of cell lysate was saved as 
an input sample as shown in figure 3.6A (lane 1 non-treated cells and lane 2 treated 
cells upper panels). Co-immunoprecipitation was continued after overnight incubation, 
the samples were washed by TNN buffer then loaded on the same 7.5% acrylamide gel 
(figure 3.6A, lower panels). The immune-precipitates brought down using TTC5 
antibody were analysed with H300 total GR specific antibody and non-specific 
secondary anti-mouse IGg.  Extracts were incubated with separate cell lysate at 40C and 
loaded on the same gel to confirm there is no non-specific interactions.  
The results showed down regulation of total GR protein levels isolated from hormone 
treated cells in the input sample in lane 1 and 2. At molecular weight 49 TTC5 levels 
increase with hormone treatment as shown in lane 1 and 2. On the other hand, in the 
88 
 
third panel co-immunoprecipitation showed that GR interacts with TTC5 in lung cancer 
cells and this, interaction increases in presence of dexamethasone (compare lanes 1 and 
in the  2) in the third panel.  Panel four showed no interaction when nonspecific 
antibody was used. Quantification showed interaction between TTC5 and GR that was 
slightly higher in treated cells (figure 3.6B). 
 
 
Figure 3.6 Interaction of TTC5 and total GR (A) Co-IP of TTC5 with total GR 40 µl of 
cell lysate (input) of non-treated cells and treated cells are loaded in lane l and 2 respectively 
(two upper panels). The immune-precipitant of treated and non-treated cells were shown in the 
third panel. Fourth panel shows non-specific anti-mouse IGg to ensure there was no non-
specific interaction. (B) The results of quantification using Image J are shown (figure 3.6, B).  
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Figure3.7| TTC5 interaction with GR phosphorylated at S211. Above described 
experiment (Figure 3.6) was used to analyse western blot membrane with antibodies 
against GR phosphorylated at S211The experiment was done by loading 40µl of cell 
lysate as input (lane1 and 2) (upper panel) and incubation of the rest of the sample with 
5µl of TTC5 antibody (both treated and non-treated cells) and developing the blot by 
incubating with antibody against phosphorylated GR at S211 (middle panel). (B) 
Quantification of results using Image J 
In order to determine if GR phosphorylated on S211 interacts with TTC5, membranes 
were reprobed with antibody that specifically detects this GR phosphorylated form. 
Results show there is a strong interaction between GR phosphorylated at S211 and 
TTC5. However, this experiment needs to be repeated multiple times to confirm the 
findings. 
 
 
3.4 Conclusion of the Co-immune precipitation  
 In summary, GR and TTC5 have been shown to interact in A549 cells according to one 
preliminary result (Figures 3.6 and 3.7, Supplementary figure 4. 2). This interaction 
increases in hormone treated cells and both total and GR phosphorylated at S211 
interact with TTC5. However, given that there was more TTC5 in hormone treated cells 
in the input sample, more experiments are needed to confirm what the role of hormone 
is in controlling GR and TTC5 interaction. 
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3.5 Determination of protein expression in human lung tissues using 
immunohistochemistry 
The main purpose of immunohistochemistry analysis was to investigate the extent of 
protein expression in healthy non-smokers, healthy ex-smokers, healthy smokers, ex-
smokers with COPD and current smokers with COPD in relation to FEV1 and clinical 
relevance in each group. Three main forms of glucocorticoids were detected in addition 
to TTC5 and IL6. The total glucocorticoid receptor (detected using H300 antibody), 
phosphorylated glucocorticoid receptor (phosphorylated on serine 226 and serine 211) 
and cofactor (TTC5) in addition to IL6, were detected in COPD patients using H300, 
S226, S211, TTC5 and IL6 specific antibodies.  
 
3.6 Optimization of experimental conditions 
The aim of optimization was to confirm specificity to antibodies and to achieve the best 
dilution for the antibodies relevant to pre-treatment condition. It was important to test 
serial sections with different buffers and the same antibody. The antibodies directed 
against phospho-serine groups of glucocorticoid receptor were better detected in buffers 
containing EDTA and Tris-EDTA. 
Conclusion from antibody optimisation protocols (figure 3.8) was that antibody against 
total GR (H300), and TTC5 antibodies do not require any pre-treatment (column 1) 
whereas the antibody against IL6 is more efficient if citrate buffer (column 2) was 
used.GR antibody that detects GR phosphorylated at serine 211 required pre-treatment 
with EB buffer (column 3) while S226 phospho GR antibody required pre-treatment in 
TEB buffer (column 4). 
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Figure 3.8 antibody optimisation  
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3.7 Pathological changes 
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Figure 3.9| Glucocorticoid receptors, phosphorylated glucocorticoid receptors, 
interleukin-6 and TTC5 were investigated in situ using immunohistochemistry in 
healthy non-smokers. 40 times magnification (column-A) of peripheral lung samples 
from healthy non-smokers, detecting the glucocorticoid receptors (H300 antibody), 
phosphorylated glucocorticoid receptors (antibodies against phosphorylated GR at S211 
and at S226) in addition to IL-6 and TTC5. 400 times magnification (column B) of the 
peripheral lung tissue analysed as described above.  
In order to analyse pathological changes in the lung tissue of healthy non-smokers, 
immune histochemical analysis was carried out using relevant antibodies (Figure 3.9 
and supplementary figure 5.4 in the appendix). The lung parenchymal tissue was intact 
(between the brackets, figure 3.9 column A, first panel from the top) in the majority of 
the involved group. The intima of blood vessels was intact (red arrow) and normal 
epithelial surface and submucosa (blue arrow, figure 3.9 column A, first panel from the 
top) with sub-mucosal gland (blue inferior arrow). In the candidate group the inner 
alveolar septum was intact (Figure 3.9 column B purple arrow). The expression of TGR, 
S211 and S226 was high in epithelial surface. However, TTC5 showed weak expression 
in epithelial surface. Moreover, IL6 was not expressed in epithelial surface of healthy 
non-smokers (Figure 3.9 column A, yellow arrow). TGR was highly expressed in 
macrophages (column-B, black arrow) and epithelial surface (Column B-red arrow). 
S211 and S226 was highly expressed in macrophages (red arrow, column B) and 
epithelial surface of healthy individuals. TTC5 showed higher expression in 
macrophages among healthy non-smokers, however expression in epithelial surface was 
relatively week. The expression of IL6 in healthy non-smokers was not detected in 
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epithelial surface, however there was some expression of IL-6 in macrophages in 
healthy normal individuals (red arrow). 
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Figure 3.10. Glucocorticoid receptors, phosphorylated glucocorticoid receptors, 
interleukin-6 and TTC5 were investigated in situ using immunohistochemistry in 
healthy ex-smokers. 40 times magnification (column-A) of peripheral lung samples 
from healthy ex-smokers, detecting the glucocorticoid receptors (H300 antibody), 
phosphorylated glucocorticoid receptors (antibodies against phosphorylated GR at S211 
and at S226) in addition to IL-6 and TTC5. 400 times magnification (column B) of the 
peripheral lung tissue analysed as described above. 
In order to analyse pathological changes in the lung tissue of healthy ex-smokers, 
immune-histochemical analysis was carried out using relevant antibodies (figure 3.10 
and supplementary figure 5.4 in the appendix). The lung parenchyma was intact in the 
majority of the patients, infiltrated with small number of macrophages (figure 3.10, 
column B) and the epithelial surface was intact (figure 3.10, yellow arrow, fist panel). 
TGR, S211, S226, and TTC5 were highly expressed in both epithelial and macrophages, 
moreover, IL6 was expressed in the epithelial surface in this group (red arrow, the last 
panel, column B). The number of macrophages infiltrating the lung parenchyma was 
low and expressing TGR, S211, S226, TTC5 and IL6 (black arrow, column B). 
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Figure 3.11| Glucocorticoid receptors, phosphorylated glucocorticoid receptors, 
interleukin-6 and TTC5 were investigated in situ using immunohistochemistry in 
healthy chronic smokers. 40 times magnification (column-A) of peripheral lung samples 
from healthy chronic smokers, detecting the glucocorticoid receptors (H300 antibody), 
phosphorylated glucocorticoid receptors (antibodies against phosphorylated GR at S211 
and at S226) in addition to IL-6 and TTC5. 400 times magnification (column B) of the 
peripheral lung tissue analysed as described above.  
In order to analyse pathological changes in lung tissue of healthy chronic smokers, 
immune-histochemical analysis was carried out using relevant antibodies (figure 3.11 
and supplementary figure 5.4 in the appendix). The lung parenchyma was intact, 
infiltrated with large number of macrophages. The expression of TGR, S211, TTC5 and 
IL6 was expressed in both macrophages and epithelial surface, additionally other 
leukocytes express IL6 in this group of patients (red arrow, figure 3.12, column B, the 
last panel). S226 was only expressed in macrophages and absent in epithelial surface 
(green arrow, figure 3.11, column B, third panel).  
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Figure 3. 12| Glucocorticoid receptors, phosphorylated glucocorticoid receptors, 
interleukin-6 and TTC5 were investigated in situ using immunohistochemistry in COPD 
ex-smokers. 40 times magnification (column-A) of peripheral lung samples from COPD 
ex-smokers, detecting the glucocorticoid receptors (H300 antibody), phosphorylated 
glucocorticoid receptors (antibodies against phosphorylated GR at S211 and at S226) in 
addition to IL-6 and TTC5. 400 times magnification (column B) of the peripheral lung 
tissue analysed as described above. 
In order to analyse pathological changes in lung tissue of COPD chronic smokers, 
immune-histochemical analysis was carried out using relevant antibodies (figure 3.12 
and supplementary figure 5.4 in the appendix). The lung parenchyma was intact in the 
majority of the patients, with some epithelial disruption. Moreover, the parenchyma was 
infiltrated with variable number of inflammatory cells including macrophages (figure 
3.12, black arrows, column B), groups of lymphocytes (figure 3.12, yellow arrows, 
column A, first panel). The expression of TGR, S211 and IL6 in macrophages and 
epithelial cells was relatively high, however, S226 was not expressed in the epithelial 
cells.  
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Figure 3.13| Glucocorticoid receptors, phosphorylated glucocorticoid receptors, 
interleukin 6 and TTC5 were investigated in situ using immunohistochemistry in COPD 
current smokers. 40 times magnification (column-A) of peripheral lung samples from 
COPD current smokers, detecting the glucocorticoid receptors (H300 antibody), 
phosphorylated glucocorticoid receptors (antibodies against phosphorylated GR at S211 
and at S226) in addition to IL-6 and TTC5. 400 times magnification (column B) of the 
peripheral lung tissue analysed as described above. 
In order to analyse pathological changes in lung tissue of COPD chronic smokers, 
immune-histochemical analysis was carried out using relevant antibodies (figure 3.12 
and supplementary figure 5.4 in the appendix). The lung parenchyma was destructed in 
the majority of cases (brackets, figure 3.13, column A and B, second panel). The 
expression of TGR, S211, S226 and IL6 was relatively high in macrophages, however, 
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TTC5 was weak expression to TTC5 in macrophages (Figure 3.13, red arrow, column 
B, and fifth panel). S226 was not expressed in epithelial surface of this group. 
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3.8 Statistical analysis 
Non-parametric repeated measures ANOVA, were used to examine the difference of 
gene expression between different groups, and multiple linear regression was performed 
for the complete data to test expression of TGR, S211, S226, TTC5 and IL-6 in relation 
to FEV1, FEV1/FVC and pack years of smoking. 
 
 
 
 
Figure 3. 14| Expression of TGR in macrophages in healthy non-smokers, healthy ex-
smokers, healthy current smokers, ex-smokers and current smokers with COPD. (A) 
Percentage of macrophages expressing TGR as demonstrated by immunohistochemistry 
in 39 patients. (B) Linear regression analysis was employed to analyse the relation 
between TGR and FEV1, FEV1/FVC and the smoking history. Error bars represent SD 
and the P vale was > 0.05. 
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Expression of TGR was analysed in macrophages in the lung tissue of healthy non-
smokers, healthy ex-smokers, healthy current smokers, ex-smokers and current smokers 
with COPD using immunohistochemistry (Figure 3.14). Expression of TGR was almost 
the same in all candidate group without any significant difference (figure 3.14A, 
compare healthy non-smokers with other group). Linear regression analysis was 
performed to determine the relation between expression of TGR and FEV1, FEV1/FVC, 
and smoking history of all candidate groups using one way anova. The analysis showed 
no significant relation between TGR and FEV1, FEV1/FVC or smoking history 
(Complete supplementary figures shown in appendix 5.5). 
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Figure 3.15| expression of S226 in healthy non-smokers, healthy ex-smokers, Healthy 
current smokers and ex-smokers and current smokers with COPD. (A) Percentage of 
macrophages expressing S226 as demonstrated by immunohistochemistry in 39 
patients. (B) Linear regression analysis was employed to analyse the relation between 
S226 and FEV1. Error bars represent SD and the P value was > 0.05. 
 
Expression of S226 was analysed in macrophages in the lung tissue of healthy non-
smokers, healthy ex-smokers, healthy current smokers and ex-smokers and current 
smokers with COPD using immunohistochemistry (figure 3.15). There was non-
significant difference in expression of S226 between the candidate groups (figure 
3.15A, compare different groups). Linear regression analysis was performed to 
determine the relation between expression of S226 and FEV1, FEV1/FVC and smoking 
history using one way anova. This analysis showed non-significant relation between 
lung parameters and S226 (complete supplementary figure shown in appendix 5.5).    
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Figure 3.16| Expression of S211 in macrophages in lung tissue in healthy non-smokers, 
healthy ex-smokers, healthy current smokers, ex-smokers and current smokers with 
COPD. (A) Percentage of macrophages expressing S211 as demonstrated by 
immunohistochemistry in 39 patients. (B) Linear regression analysis was employed to 
analyse correlation between S211 and lung parameters. Error bars represent SD and the 
P value was > 0.05.  
Expression of S211 was analysed in macrophages in the lung tissue of healthy non-
smokers, healthy ex-smokers, healthy current smokers, ex-smokers and current smokers 
with COPD using immunohistochemistry (figure 3.17). S211 was exist in all candidate 
group without significant difference (figure 3.16A, compare different groups). Linear 
regression analysis was performed to determine the relation between the expression of 
S211 and FEV1, FEV1/FVC, and smoking history using one way anova. This showed 
non-significant relation between the expression of S211 and lung parameters or 
smoking history (complete supplementary figure shown in appendix 5.5) 
112 
 
 
 
Data 1
50 100 150
-10
0
10
20
30
FEV1%
m
a
c
s
 e
x
p
re
s
s
in
g
 I
L
6
      
Figure 3.17| Expression of IL6 in Macrophages in Healthy non-smokers, healthy ex-
smokers, healthy current smokers, ex-smokers and current smokers with COPD. (A) 
Percentage of macrophages expressing IL6 as demonstrated by immunohistochemistry 
in 39 patients. (B) Linear regression analysis was employed to analyse correlation 
between IL6 and FEV1. Error bars represent S.D and the P value was > 0.05. 
The expression of IL-6 was analysed in macrophages in the lung tissue of healthy non-
smokers, healthy ex-smokers, healthy current smokers, ex-smokers and current smokers 
with COPD using immunohistochemistry (figure 3.17). The statistical analysis showed 
no significant difference in the expression of IL-6 among the candidate group (figure 
3.17A, compare different groups). Linear regression analysis was performed to 
determine the relation between IL-6 expression and FEV1/FVC, FEV1 and smoking 
status of all candidate group using one way anova. This analysis showed non-significant 
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relation between the expressions of IL-6 and lung parameters or smoking status 
(complete supplementary figure shown in appendix 5.5).                                                 
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Figure 3.18 Expression of TTC5 in macrophages in healthy non-smokers, healthy ex-
smokers, healthy current smokers, ex-smokers and current smokers with COPD. (A) 
Number of macrophages expressing TTC5 as demonstrated by 
immunohiustochemistry.in 39 patients. (B) Linear regression analysis was employed to 
analyse correlation between TTC5 and FEV1/FVC.  Error bars represent SD. P value 
was < 0.05. 
Expression of TTC5 was analysed in macrophages in the lung tissue of healthy non-
smokers, healthy ex-smokers, healthy current smokers, ex-smokers and current smokers 
with COPD using immunohistochemistry (Figure 3.18).  Expression of TTC5 was at 
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highest level in healthy non-smokers and its expression showed gradual decrease as 
disease progressed. Moreover there was significant decrease between healthy non-
smokers and current smokers with COPD (figure 3.18A, compare healthy non-smokers 
group to current smokers with COPD).  Linear regression analysis was performed to 
determine the relation between expression of TTC5 and FEV1/FVC, FEV1 and 
smoking history of all candidate groups using one way anova. This analysis showed 
significant relation between FEV1/FVC and TTC5, in which the percentage of 
macrophages expressing TTC5 are declining with the course of the disease P value 
<0.05. (Complete supplementary figure shown in appendix 5.5) 
 
The expression in epithelial cells among healthy non-smokers, current healthy smokers, 
and current smokers with COPD, showed significant difference between healthy 
individuals and current smokers with COPD. The expression of IL6 was at the highest 
level among COPD patients who currently smoke, while healthy normal individuals 
showed no expression to IL-6. The expression of S226 in epithelial cells among healthy 
non-smokers, current smokers and COPD current smokers showed significant 
difference, in which the expression of S226 was higher among healthy non-smokers and 
very weak expression among current smokers and COPD patients. TGR, S211 and 
TTC5 were expressed among all candidate group (healthy non-smokers, current healthy 
smokers, and COPD patients). 
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Conclusion 
TGR, S226, S211 showed no significant difference in expression among healthy non-
smokers, healthy current smokers and current or ex-smokers with COPD, however the 
expression of IL-6 in both macrophages and epithelial cells was significantly different 
and increase by disease course. The percentage of average positive macrophages to 
TTC5 among healthy non-smokers was the highest and decrease gradually over the 
course of the disease. 
Expression of S226 and IL-6 were opposite to each other in epithelial cells, in which 
healthy non-smokers showed no expression to IL6 and high expression to S226. On the 
other hand in COPD patients the IL6 was highly expressed and S226 was negative. 
(Complete supplementary table for clinical features, and statistical analysis including 
the averages supplemented in complete tables 4.4 and 4.5). 
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Discussion  
The disease course in COPD varies from one patient to another, and treatment failure is 
common. Glucocorticoids are among the most widely prescribed drugs for the 
management of COPD, however, glucocorticoid resistance is the main obstacle in the 
management of COPD (Sin et al, 2003). Glucocorticoids in humans are secreted in a 
circadian rhythm in the form of cortisol under the control of the HPA (hypothalamic 
pituitary axis). The receptors mediating the glucocorticoid effect can be altered and are 
considered to be inflammatory markers in some diseases, such as asthma and COPD 
(Vilasco et al, 2011). The aim of this research is to follow the molecular pathways of 
the glucocorticoid hormone and of the stress co-factor TTC5. A further aim is to 
measure the expression of IL-6 and of the glucocorticoid receptors in peripheral parts of 
the lungs across different groups: COPD current smokers, COPD ex-smokers, healthy 
smokers, healthy ex-smokers and healthy non-smokers. 
 
4.1 Disease progression and glucocorticoid resistance 
Glucocorticoid receptors control many physiological functions, such as cellular 
differentiation and metabolism, by modulating transcription in cells in a gene specific 
way (Mushtaq et al, 2002). There are two forms of glucocorticoid receptors, hGR-α and 
hGR-β. The GR-α is the most abundant form. Furthermore, the level in the cells of GR-
α mRNA is higher than that of GR-β mRNA (Pujols et al, 2002). We have analysed the 
expression of the hGR-α form in A549 cells (respiratory epithelial lining cells) under 
the effect of dexamethasone. Wang et al, (2002) have identified three main 
phosphorylation points at N-terminal transcriptional regulatory domains (S203, S211 
and S226).   
To gain insight into the effect of dexamethasone on the transcriptional activity of GR, 
we have investigated the effect of dexamethasone on TGR, on phosphorylated GR at 
S211 and S226, and on the stress co-factor TTC5. Our results show that the protein 
level of both phosphorylated forms of glucocorticoid receptors is up-regulated 
significantly in the presence of the dexamethasone hormone.  
TTC5 (stress responsive activator of P53) or strap is a p300 interacting protein, which is 
necessary for P53 response (Demonacos et al, 2001). We have investigated the effect of 
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dexamethasone on TTC5 in A549 cells and the result shows varying degrees of up-
regulation. Previously it has been proposed that glucocorticoid activity is linked to the 
TTC5 cofactor that affects its stability and transcriptional activity (Demonacos et al, 
2001). Demonacos et al (2011) have stated that TTC5 interacts with TGR in the 
presence and absence of dexamethasone at multiple sites. Our data are consistent with 
this result. Our preliminary data show that there is an interaction between TTC5 and 
phosphorylated GR at S211. 
 
4.2 Evaluation of glucocorticoid receptors, TTC5 and IL-6 in COPD patients 
Glucocorticoids usually halt the inflammatory process by reversing the histone 
acetylation of activated genes (Barnes, 2010). As a result of oxidative and nutritive 
stress, histone deacetylase activity decreases in COPD patients, leading to 
glucocorticoid resistance (Barnes, 2010). Chronic obstructive pulmonary disease 
(COPD) is a progressive, non-reversible decline in FEV1 due to airflow limitation and 
parenchymal destruction (Rabe et al, 2007; MacNee et al, 2007). Many types of cell are 
involved in the pathogenesis of this disease. One type, epithelial cells, is activated to 
produce inflammatory mediators, including TNF-α, IL-1b and IL-6. In addition, 
epithelial cells are an important source of TGF, which mediates fibrosis. 
In this study, we have evaluated a cohort of 39 patients of different categories and 
examined the expression of TGR, S211, S226, TTC5 and IL-6 in relation to spirometry 
changes FEV1, the FEV1/FVC ratio, smoking status, and the stage of the disease. In 
addition, a linear regression curve was used to detect the relationship between smoking 
history, FEV1 and the FEV1/FVC ratio.  
Jan et al (2011) found that TGR was expressed in all groups in both macrophages and 
epithelial cells, showing that there is no significant difference between healthy non-
smokers and COPD patients in TGR expression. 
Our results show that total glucocorticoid receptor (TGR) is expressed in both 
macrophages and epithelial cells of all candidate involving current smokers with COPD 
without any significant changes in the expression. The linear regression curve shows 
that the alteration of FEV1 is not related to glucocorticoid receptor expression. To gain 
insight into the expression of phosphorylated GR at S211 in the peripheral lung tissue, 
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we have analysed the same candidate groups of patients: healthy non-smokers, heathy 
ex-smokers, heathy smokers and both ex-smokers and current smokers with COPD. Our 
results show that the GR phosphorylated at S211 was expressed in all the groups and 
there was no significant difference in the expression between the candidate groups. 
The phosphorylation of S226 on the GR is mediated by C-Jun terminal kinase, a 
member of MAPK (mitogen activated protein kinase), which blocks GR transcriptional 
activation (Rogastsky et al, 1998). Ito et al (2002) revealed that S226 phosphorylation 
controls GR export from the nucleus upon hormone withdrawal. Our statistical analysis 
showed that the percentage of macrophages expressing S226 in peripheral lung tissue in 
all patients is more or less the same. However, GR phosphorylation at S226 was 
expressed in the epithelial cells only of healthy non-smokers, suggesting that S226 
activity can be altered by smoking. 
Moreover, we investigated a novel expression of TTC5 in the peripheral lung tissue. For 
different groups of patients, our statistical analysis shows that TTC5 expression in 
peripheral lung tissue is altered by smoking status and the progression of the disease. 
TTC5 expression in macrophages is inversely proportionate to the FEV1/FVC ratio and 
the linear regression curve shows a positive curve line (P value < 0.5).  
We also investigated the expression of TTC5 in the epithelial cells of heathy non-
smokers, healthy ex-smokers, heathy current smokers and both ex-smokers and current 
smokers with COPD. Our data shows that TTC5 is expressed in all the candidate 
groups.  
 
4.3 Pro-inflammatory cytokines and COPD 
Frequent contact of the epithelial surface with noxious antigens may precipitate the 
inflammatory process by means of inflammatory mediators including TNF-α, IL-1b and 
IL6, secreted from the inflammatory cells such as macrophages, neutrophils, T-
lymphocytes, and pulmonary epithelial cells. The epithelial surface plays a role in 
airway remodelling (Perotin et al, 2014). In this research, we have evaluated the 
expression of pro-inflammatory cytokines IL-6 in the epithelial cells of COPD patients 
compared to normal healthy individuals. Our data revealed that IL6 is not expressed in 
healthy non-smokers, whereas in both heathy ex-smokers and COPD patients epithelial 
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cells express IL6, suggesting that exposure to cigarette smoke stimulates pulmonary 
epithelial cells to release IL-6.  
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Conclusion  
Glucocorticoids play a pivotal role in both lung development and treatment and act by 
binding to intracellular protein glucocorticoid receptors (GR). Glucocorticoids are 
among the most widely prescribed drugs in the world for inflammatory diseases, such as 
rheumatoid arthritis, COPD and cases of malignancy like leukaemia, skin and numerous 
other conditions. They are regularly used in the treatment of lung diseases, such as 
asthma, because of their anti-inflammatory properties. However, resistance and side 
effects remain problems, highlighting the need for further research.  
The aim of this project is to understand the basis of glucocorticoid resistance in COPD 
and in non-small cell lung cancers (adenocarcinoma). The glucocorticoid receptor 
function is controlled at multiple levels, including covalent modifications, the GR 
interaction with transcriptional co-factors such as TTC5 that is involved in control of its 
target genes and ligand type. In this project, glucocorticoid receptors phosphorylation 
and interaction with its cofactors were investigated in A549 cell lines and COPD 
patients. The samples were obtained from Wythenshawe hospital after surgical 
procedures and the analysis was far from the affected area. The results indicated that the 
GR and the cofactor TTC5 were expressed in lung cancer cell line A549, that GR is 
phosphorylated in that cell line, and that it can interact with TTC5. 
Immunohistochemistry analysis of different stages in COPD patients (categorised 
according to whether they smoke, or have COPD or cancer) was carried out to detect the 
total GR, GR phosphorylated at serine 211 and serine 226, and the expression of TTC5 
and interleukin 6. The expression of these proteins was then correlated with the clinical 
picture for TTC5, in which TTC5 was highly expressed in heathy non-smokers and the 
level of expression decreased gradually among the candidate groups, with a significant 
difference between healthy non-smokers and current smokers with COPD. Moreover, 
the level of TTC5 expression in all the candidate groups was directly proportionate to 
FEV1/FVC ratio. The results of this research may improve therapy efficacy and help 
minimize the unwanted effects of steroids used in lung pathologies. 
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Future prospectus 
In this thesis, we examined the expression of TTC5 in macrophages in different stages 
of COPD. However, the effect of dexamethasone on TTC5 expression in macrophages 
needs to be investigated. The interaction between TTC5 and glucocorticoid receptors in 
macrophages is unknown. Our future prospectus is the identification of TTC5 compared 
to the degree of inflammation in peripheral lung tissue, using real time PCR and 
isolation of macrophages from COPD patients to determine the interaction between 
TTC5 and GR, compared with healthy candidates.  
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